(FILE 'HOME' ENTERED AT 10:07:38 ON 12 SEP 2003)

FILE 'REGISTRY' ENTERED AT 10:07:50 ON 12 SEP 2003

L1 11 S METFORMIN OR GLIPIZIDE

FILE 'HCAPLUS, MEDLINE, BIOSIS, EMBASE, JAPIO, USPATFULL' ENTERED AT 10:08:52 ON 12 SEP 2003

L2 4879 S 338752-31-1/RN OR 338752-30-0/RN OR 88159-36-8/RN OR 29094-61

L3 1713 S 1115-70-4/RN OR METFORMIN OR GLUFORMIN OR GLYFORMIN OR GLUME

L4 1717 S L3 OR 58840-24-7/RN OR 53950-18-8/RN OR 38950-16-2/RN OR 344

L5 404 S L4 AND L2

L6 394 DUP REM L5 (10 DUPLICATES REMOVED)

L7 183 S L6 AND (SINGLE DOSAGE OR TABLE OR CAPSULE OR SINGLE DOSE)

L8 183 FOCUS L7 1-

6303146

11 ANSWER 1 OF 56 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:944287 HCAPLUS
DOCUMENT NUMBER: 138:100731
TITLE: **Glyburide/metformin** combination product is safe and efficacious in patients with type 2 diabetes failing sulfonylurea therapy
AUTHOR(S): Blonde, L.; Rosenstock, J.; Mooradian, A. D.; Piper, B.-A.; Henry, D.
CORPORATE SOURCE: Ochsner Clinic Foundation, New Orleans, LA, USA
SOURCE: Diabetes, Obesity and Metabolism (2002), 4(6), 368-375
CODEN: DOMEF6; ISSN: 1462-8902
PUBLISHER: Blackwell Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The aim was to compare the efficacy, safety and tolerability of a fixed combination **glyburide/metformin** prepn. with those of glyburide or metformin alone in patients with type 2 diabetes inadequately controlled by sulfonylurea, diet and exercise. In this 16-wk, randomized, double-blind, parallel group study, 639 patients with inadequate glycemic control on at least half-maximal dose of sulfonylurea were randomly assigned to: glyburide 10 mg b.i.d. (n = 164); metformin 500 mg (n = 153); **glyburide/metformin** 2.5 mg/500 mg (n = 160); or **glyburide/metformin** 5 mg/500 mg (n = 162). Titrn. was allowed to max. doses of 2000 mg for metformin or 10 mg/2000 mg and 20 mg/2000 mg for **glyburide/metformin** 2.5 mg/500 mg and 5 mg/500 mg resp. The primary outcome measure was HbA1c level after 16 wk; secondary end-points included fasting and 2-h post-prandial plasma glucose. Adverse events (AEs) were recorded and summarized by treatment group. Both strengths of **glyburide/metformin** equally reduced mean HbA1c by 1.7% more than did glyburide alone ($p < 0.001$), and by 1.9% more than did metformin alone ($p < 0.001$). Final mean fasting plasma glucose concns. were also lower in both **glyburide/metformin** groups than in the glyburide (-2.8 mmol/l, -51.3 mg/dL; $p < 0.001$) and metformin groups (-3.6 mmol/l, -64.2 mg/dL; $p < 0.001$). Safety and tolerability were similar across all treatment groups, except for a higher incidence of gastrointestinal AEs in the metformin monotherapy group, and more patients reporting mild or moderate symptoms of hypoglycemia while taking **glyburide/metformin**. Both **glyburide/metformin** tablet strengths produced, with equal efficacy, significantly better glycemic control than monotherapy with either agent. These data also confirm that glycemic efficacy does not require maximal sulfonylurea doses in combination with metformin.

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CCESSION NUMBER: 2002:499506 HCAPLUS
DOCUMENT NUMBER: 137:119415
TITLE: Simultaneous **glyburide/metformin** therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes
AUTHOR(S): Garber, A. J.; Larsen, J.; Schneider, S. H.; Piper, B. A.; Henry, D.
CORPORATE SOURCE: Baylor College of Medicine and The Methodist Hospital, Houston, TX, 77030, USA
SOURCE: Diabetes, Obesity and Metabolism (2002), 4(3), 201-208
CODEN: DOMEF6; ISSN: 1462-8902
PUBLISHER: Blackwell Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The aim of this study was to evaluate whether simultaneous initial treatment of both insulin resistance and impaired .beta.-cell insulin secretion with **glyburide/metformin** tablets is superior to monotherapy with each component agent. In this randomized, parallel-group, placebo-controlled, multicenter study, 806 patients with type 2 diabetes (mean duration, 3 yr) who had failed diet and exercise were randomly assigned to 4 wk of therapy with placebo, glyburide 2.5 mg, metformin 500 mg, **glyburide/metformin** 1.25/250 mg, or **glyburide/metformin** 2.5/500 mg once daily. Doses were then titrated over 8 wk based on glycemic response. The primary outcome measure was change from baseline in mean HbA1c after 20 wk. Changes in fasting plasma glucose, lipids and body wt. were also assessed along with 2-h postprandial glucose and insulin values after a standardized meal. At week 20, patients taking **glyburide/metformin** 1.25/250 mg or 2.5/500 mg tablets had greater redns. in HbA1c levels (-1.48% and -1.53% resp.) compared with placebo (-0.21%; both $p < 0.001$), glyburide (-1.24%; $p = 0.016$ and $p = 0.004$ resp.) or metformin (-1.03%; both $p < 0.001$). Fasting plasma glucose concns. were reduced more in both **glyburide/metformin** groups compared with placebo and metformin ($p < 0.001$); patients in both combination therapy groups also had significantly lower postprandial glucose concns. compared with placebo, glyburide and metformin. Initial combination treatment with **glyburide/metformin** tablets produces greater improvements in glycemic control than either glyburide or metformin monotherapy. The superiority of initial therapy with **glyburide/metformin** tablets may arise from simultaneous treatment of both pathophysiol. defects of type 2 diabetes.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 56 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:842385 HCAPLUS
DOCUMENT NUMBER: 137:332944
TITLE: Lipid effects of **glyburide/metformin** tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study
AUTHOR(S): Dailey, George E., III; Mohideen, Pharis; Fiedorek, Fred T.
CORPORATE SOURCE: Diabetes and Endocrinology, Scripps Clinic, La Jolla, CA, USA
SOURCE: Clinical Therapeutics (2002), 24(9), 1426-1438
CODEN: CLTHDG; ISSN: 0149-2918
PUBLISHER: Excerpta Medica, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Because both type 2 diabetes and elevated plasma lipid levels are important independent risk factors for cardiovascular disease and coronary heart disease, the choice of an antihyperglycemic agent for patients with type 2 diabetes-in whom abnormal plasma lipid levels are often seen-should take into account effects on lipids as well as on markers of glycemic control. This study assessed the effects on lipid levels of **glyburide/metformin** tablets in the treatment of type 2 diabetes, particularly in a group of patients who had poor glycemic control and dyslipidemia at baseline. This 52-wk, open-label study was an extension of a 32-wk, double-blind, placebo-controlled study. The patient population was drawn from 3 groups: those who completed the double-blind study, those who were discontinued from the double-blind study, and those who were ineligible for the double-blind study based on predefined measures of glycemic control (screening fasting plasma glucose >240 mg/dL and glycosylated Hb [HbA1c] .ltoreq.12%, or HbA1c 11%-12%) and were directly enrolled in the open-label extension study. Patients with an HbA1c of <9% received **glyburide/metformin** tablets 1.25 mg/250 mg BID; those with an HbA1c .gtoreq.9% received **glyburide /metformin** tablets 2.5 mg/500 mg BID. Changes in total cholesterol (TC), low-d. lipoprotein cholesterol (LDL-C), high-d. lipoprotein cholesterol (HDL-C), and triglyceride (TG) levels were assessed for 52 wk. The study population included 828 patients: 515 who completed the double-blind study, 138 who were discontinued from the double-blind study, and 175 who were enrolled directly. Direct enrollees had poor glycemic control and dyslipidemia at baseline. Improvements in plasma lipid levels were seen as early as week 13. At week 52, the mean change in TC from baseline was -8.0 mg/dL for the total population (95% CI, -10.9 to -5.2; $P < 0.05$) and -23.2 mg/dL for direct enrollees (95% CI, -30.1 to -16.4; $P < 0.05$). The mean decrease in LDL-C from baseline for the total population was 2.86 mg/dL (95% CI, -5.3 to -0.4; $P < 0.05$), compared with a redn. of 13.3 mg/dL for direct enrollees (95% CI, -18.5 to -8.1; $P < 0.05$). Mean HDL-C levels were minimally affected. Mean TG levels decreased by 27.8 mg/dL for the entire population (95% CI, -4.2.9 to -12.8; $P < 0.05$) and by 99.7 mg/dL for direct enrollees (95% CI,-152.5 to-46.8; $P < 0.05$). In this open-label extension study, treatment with **glyburide/metformin** tablets for type 2 diabetes had a durable, favorable effect on lipid levels, particularly in those with poor glycemic control and dyslipidemia at baseline.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:557424 HCAPLUS
TITLE: Simultaneous **glyburide/metformin** therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. [Erratum to document cited in CA137:119415]
AUTHOR(S): Garber, A. J.; Larsen, J.; Schneider, S. H.; Piper, B. A.; Henry, D.
CORPORATE SOURCE: Baylor College of Medicine and The Methodist Hospital, Houston, TX, 77030, USA
SOURCE: Diabetes, Obesity and Metabolism (2002), 4(4), 286
CODEN: DOMEF6; ISSN: 1462-8902
PUBLISHER: Blackwell Science Ltd.
DOCUMENT TYPE: Journal; Errata
LANGUAGE: English
AB An erratum.

L11 ANSWER 5 OF 56 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:842383 HCAPLUS
DOCUMENT NUMBER: 137:332943
TITLE: Durability of efficacy and long-term safety profile of **glyburide/metformin** tablets in patients with type 2 diabetes mellitus: an open-label extension study
AUTHOR(S): Garber, Alan J.; Bruce, Simon; Fiedorek, Fred T.
CORPORATE SOURCE: Baylor College of Medicine and the Methodist Hospital, Houston, TX, USA
SOURCE: Clinical Therapeutics (2002), 24(9), 1401-1413
CODEN: CLTHDG; ISSN: 0149-2918
PUBLISHER: Excerpta Medica, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Intensive glycemic control substantially reduces the microvascular and macrovascular complications of type 2 diabetes mellitus, although less than half of patients with diabetes achieve the target glycosylated Hb (HbA1c) value recommended by the American Diabetes Assocn. Because monotherapy with an oral agent does not address the multiple pathophysiol. defects of diabetes, use of combination therapy appears to be warranted. A previous 32-wk, randomized, double-blind, placebo-controlled trial found that treatment with **glyburide/metformin** tablets was assocd. with greater redns. in HbA1c values compared with glyburide monotherapy, metformin monotherapy, and placebo. This study evaluated the durability of efficacy and long-term safety profile of therapy with **glyburide/metformin** tablets over 52 wk. Patients enrolled in this open-label extension study were drawn from 3 groups: those who completed the 32-wk double-blind study, those who were discontinued from the double-blind study, and those who were ineligible for the double-blind study and were enrolled directly in the open-label extension study. Patients with an HbA1c of <9% received **glyburide /metformin** 1.25 mg/250 mg tablets BID, and those with an HbA1c of .gtoreq.9% received **glyburide/metformin** 2.5 mg/500 mg tablets BID. Primary efficacy variables included changes from baseline in HbA1c, fasting plasma glucose (FPG), and body wt. at week 52. Safety was assessed based on adverse-event data and the results of phys. examns. and lab. tests. A total of 828 patients were enrolled in the study: 515 who completed the 32-wk double-blind study, 138 who were discontinued from the double-blind study, and 175 who were directly enrolled. At week 52, the mean HbA1c value for the entire population had decreased from a baseline value of 8.73% to 7.04% (95% CI, -1.81 to -1.58). Patients who were enrolled directly had the poorest glycemic control at baseline and experienced the greatest redn. in HbA1c (-3.35%; 95% CI, -3.61 to -3.10). A redn. in mean FPG for the total population was obsd. as early as week 2, from 201 to 141 mg/dL (95% CI, -63.0 to -55.7). Symptoms of hypoglycemia occurred in 19.9% (165/828) of patients, although only one third of these patients had a documented finger-stick blood glucose value of .ltoreq.50 mg/dL. In this 52-wk, open-label extension study, **glyburide/ metformin** tablets were well tolerated and effective in patients with type 2 diabetes. They provided rapid and sustainable redns. in HbA1c values and FPG concns.

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CCESSION NUMBER: 2003:657740 HCAPLUS
TITLE: Efficacy of **glyburide/metformin** tablets compared with initial monotherapy in type 2 diabetes
AUTHOR(S): Garber, Alan J.; Donovan, Daniel S., Jr.; Dandona, Paresh; Bruce, Simon; Park, Jong-Soon
CORPORATE SOURCE: Baylor College of Medicine and the Methodist Hospital, Houston, TX, 77030, USA
SOURCE: Journal of Clinical Endocrinology and Metabolism (2003), 88(8), 3598-3604
CODEN: JCEMAZ; ISSN: 0021-972X
PUBLISHER: Endocrine Society
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Many patients with type 2 diabetes fail to achieve or maintain the American Diabetes Assocn.'s recommended treatment goal of glycosylated Hb levels. This multicenter, double-blind trial enrolled patients with type 2 diabetes who had inadequate glycemic control [glycosylated Hb A1C (A1C), >7% and <12%) with diet and exercise alone to compare the benefits of initial therapy with **glyburide/metformin** tablets vs. metformin or glyburide monotherapy. Patients (n = 486) were randomized to receive **glyburide/metformin** tablets (1.25/250 mg), metformin (500 mg), or glyburide (2.5 mg). Changes in A1C, fasting plasma glucose, fructosamine, serum lipids, body wt., and 2-h postprandial glucose after a standardized meal were assessed after 16 wk of treatment. **Glyburide/metformin** tablets caused a superior mean redn. in A1C from baseline (-2.27%) vs. metformin (-1.53%) and glyburide (-1.90%) monotherapy (P = 0.0003). **Glyburide/metformin** also significantly reduced fasting plasma glucose and 2-h postprandial glucose values compared with either monotherapy. The final mean doses of **glyburide/metformin** (3.7/735 mg) were lower than those of metformin (1796 mg) and glyburide (7.6 mg). First-line treatment with **glyburide/metformin** tablets provided superior glycemic control over component monotherapy, allowing more patients to achieve American Diabetes Assocn. treatment goals with lower component doses in drug-naive patients with type 2 diabetes.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:564950 HCAPLUS
TITLE: **Glyburide/metformin** tablets: a new therapeutic option for the management of Type 2 diabetes
AUTHOR(S): Dailey, George E.
CORPORATE SOURCE: 10666 N. Torrey Pines Road, La Jolla, CA, 92037, USA
SOURCE: Expert Opinion on Pharmacotherapy (2003), 4(8), 1417-1430
CODEN: EOPHF7; ISSN: 1465-6566
PUBLISHER: Ashley Publications Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Oral antidiabetic combination therapy is a proven means of establishing glycemic control in the hyperglycemic, Type 2 diabetic patient, but co-administering two oral antidiabetic agents sep. may hinder compliance with therapy. A new single-tablet of **glyburide/metformin** combination therapy (Glucovance, Bristol-Myers Squibb, Inc.) has recently been developed, which addresses the primary defects of Type 2 diabetes: .beta.-cell dysfunction and insulin resistance. The **glyburide/metformin** tablet, taken with meals, is designed to optimize the absorption of glyburide and to address the postprandial glucose rise. **Glyburide/metformin** tablets are more effective in controlling fasting and postprandial glycemia than its component monotherapies, at lower doses of metformin and glyburide compared with monotherapy because of the synergy between its glyburide and metformin components. Moreover, a double-blind study showed that **glyburide/metformin** tablets are more effective than a free combination of glyburide co-administered with metformin in controlling postprandial glucose. Retrospective analyses suggested that **glyburide/metformin** tablets control glycated Hb (A1C) more effectively than a free combination of glyburide co-administered with metformin, at lower mean doses of glyburide and metformin. The incidence of side effects is lower than sep. component therapy for any given A1C. **Glyburide/metformin** tablets are an effective option for optimizing the control of blood glucose in Type 2 diabetic patients and appear to enhance adherence to therapy.

ACCESSION NUMBER: 2003:51312 HCAPLUS
DOCUMENT NUMBER: 138:117496
TITLE: Pharmacokinetics and pharmacodynamics of **glyburide/metformin** tablets (Glucovance) versus equivalent doses of glyburide and metformin in patients with type 2 diabetes
AUTHOR(S): Donahue, Stephen R.; Turner, Kenneth C.; Patel, Shardul
CORPORATE SOURCE: Department of Clinical Discovery, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ, USA
SOURCE: Clinical Pharmacokinetics (2002), 41(15), 1301-1309
CODEN: CPKNDH; ISSN: 0312-5963
PUBLISHER: Adis International Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Objective: To compare the effects of two different formulations of glibenclamide (glyburide) combined with metformin on postprandial glucose excursions, and to assess their pharmacokinetics. The formulations were a combination glibenclamide/metformin tablet (Glucovance; controlled-particle-size glibenclamide and metformin) vs. glibenclamide (Micronase) and metformin (Glucophage) coadministered sep. Design: A randomized, double-blind, two-way crossover study in which patients with type 2 diabetes received either glibenclamide/metformin 2.5/500mg tablets or glibenclamide 2.5mg with metformin 500mg twice daily for 14 days. After a 2-wk washout, patients were crossed over to the other treatment for 14 days. Patients consumed standardized meals on the days when pharmacokinetic and pharmacodynamic evaluations were performed. Participants: Forty patients with type 2 diabetes were enrolled; 37 were randomized (18 men, 19 women) and 35 completed the study. Mean age was 58 yr; mean body mass index was 31 kg/m2. The baseline glycated Hb (HbA1c) was 9.3% for both treatment groups. Main outcome measure: Two-hour postprandial glucose excursion (PPGE) was used to assess postprandial glucose dynamics. Results: Treatment with glibenclamide/metformin resulted in a significantly smaller mean PPGE than was attained by treatment with glibenclamide plus metformin, according to measurements taken after the day 14 afternoon standardized meal (89.5 vs. 117.4 mg/dL, $p = 0.011$). The mean glibenclamide peak concn. (Cmax) was significantly greater (.apprx.16%) after glibenclamide/metformin treatment on both days 1 and 14. Glibenclamide/metformin treatment was assocd. with a 2-fold greater area under the concn.-time curve to 3 h for glibenclamide (AUC3) [$p < 0.001$], although the AUC over the administration interval was equiv. for both formulations. Conclusion: In patients with type 2 diabetes, glibenclamide/metformin resulted in lower PPGE, suggesting that the higher glibenclamide AUC3 obsd. with this formulation may contribute to better postprandial glycemic control than is attained by glibenclamide plus metformin sep.

REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 14 OF 56 MEDLINE on STN
ACCESSION NUMBER: 2003077460 MEDLINE
DOCUMENT NUMBER: 22475941 PubMed ID: 12589230
TITLE: Beneficial effects of a **glyburide/metformin** combination preparation in type 2 diabetes mellitus.
AUTHOR: Bokhari Syed U; Gopal Usha M; Duckworth William C
CORPORATE SOURCE: Carl T. Hayden VA Medical Center, Phoenix, Arizona 85012, USA.. syed.bokhari2@med.va.gov
SOURCE: AMERICAN JOURNAL OF THE MEDICAL SCIENCES, (2003 Feb) 325 (2) 66-9.
Journal code: 0370506. ISSN: 0002-9629.
PUB. COUNTRY: United States
DOCUMENT TYPE: (CLINICAL TRIAL)
Journal; Article; (JOURNAL ARTICLE)
(RANDOMIZED CONTROLLED TRIAL)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200303
ENTRY DATE: Entered STN: 20030221
Last Updated on STN: 20030331
Entered Medline: 20030328

AB BACKGROUND: Type 2 diabetes mellitus is characterized by both insulin deficiency and insulin resistance. Effective treatment often requires therapy directed at both abnormalities. Patients on monotherapy might benefit from a combination agent such as **glyburide/metformin**, which increases insulin secretion and reduces insulin resistance. METHODS: All patients taking a **glyburide/metformin** preparation at the Carl T. Hayden VAMC were identified from pharmacy records. Patients with documented hemoglobin A values within 31 weeks prior and between 3 and 33 weeks after initiation of therapy (92 subjects) were examined. RESULTS: **Glyburide/metformin** combination therapy reduced hemoglobin A levels from 0.087 to 0.083 ($P < 0.06$). Significant reductions were seen in those patients with initial levels higher than 0.08 (0.094 to 0.087; $P < 0.01$). No significant reductions were seen in those patients with initial levels lower than 0.08. CONCLUSIONS: In patients on monotherapy or on dual oral therapy with inadequate control, changing to a **glyburide/metformin** combination preparation may improve glucose control.

ACCESSION NUMBER: 2001408485 MEDLINE
DOCUMENT NUMBER: 21082683 PubMed ID: 11460818
TITLE: Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined **glyburide/metformin** therapy over a 7.7-year follow-up.
AUTHOR: Fisman E Z; Tenenbaum A; Boyko V; Benderly M; Adler Y; Friedensohn A; Kohanovski M; Rotzak R; Schneider H; Behar S; Motro M
CORPORATE SOURCE: Cardiac Rehabilitation Institute, the Chaim Sheba Medical Center, Tel-Hashomer, Israel.
SOURCE: CLINICAL CARDIOLOGY, (2001 Feb) 24 (2) 151-8.
Journal code: 7903272. ISSN: 0160-9289.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200107
ENTRY DATE: Entered STN: 20010723
Last Updated on STN: 20021018
Entered Medline: 20010719
AB BACKGROUND: A sulfonylurea--usually glyburide--plus metformin constitute the most widely used oral antihyperglycemic combination in clinical practice. Both medications present undesirable cardiovascular effects. The issue whether the adverse effects of each of these pharmacologic agents may be additive and detrimental to the prognosis for coronary patients has not yet been specifically addressed. HYPOTHESIS: This study was designed to examine the survival in type 2 diabetics with proven coronary artery disease (CAD) receiving a combined **glyburide/metformin** antihyperglycemic treatment over a long-term follow-up period. METHODS: The study sample comprised 2,275 diabetic patients, aged 45-74 years, with proven CAD, who were screened but not included in the bezafibrate infarction prevention study. In addition, 9,047 nondiabetic patients with CAD represented a reference group. Diabetics were divided into four groups on the basis of their therapeutic regimen: diet alone (n = 990), glyburide (n = 953), metformin (n = 79), and a combination of the latter two (n = 253). RESULTS: The diabetic groups presented similar clinical characteristics upon recruitment. Crude mortality rate after a 7.7-year follow-up was lower in nondiabetics (14 vs. 31.6%, p<0.001). Among diabetics, 720 patients died: 260 on diet (mortality 26.3%), 324 on glyburide (34%), 25 on metformin alone (31.6%), and 111 patients (43.9%) on combined treatment (p<0.000001). Time-related mortality was almost equal for patients on metformin and on combined therapy over an intermediate follow-up period of 4 years (survival rates 0.80 and 0.79, respectively). The group on combined treatment presented the worst prognosis over the long-term follow-up, with a time-related survival rate of 0.59 after 7 years, versus 0.68 and 0.70 for glyburide and metformin, respectively. After adjustment to variables for prognosis, the use of the combined treatment was associated with an increased hazard ratio (HR) for all-cause mortality of 1.53 (95% confidence interval [CI] 1.20-1.96), whereas glyburide and metformin alone yielded HR 1.22 (95% CI 1.02-1.45) and HR 1.26 (95% CI 0.81-1.96), respectively. Conclusions: We conclude that after a 7.7-year follow-up, monotherapy with either glyburide or metformin in diabetic patients with CAD yielded a similar outcome and was associated with a modest increase in mortality. However, time-related mortality was markedly increased when a combined **glyburide/metformin** treatment was used.

L11 ANSWER 23 OF 56 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2001:448868 BIOSIS
DOCUMENT NUMBER: PREV200100448868
TITLE: Durable antidiabetic effect of **glyburide/metformin** tablets as initial therapy for type 2 diabetes.
AUTHOR(S): Garber, Alan J. (1); Piper, Beth Ann (1); Park, Jong-Soon (1)
CORPORATE SOURCE: (1) Houston, TX USA
SOURCE: Diabetes, (June, 2001) Vol. 50, No. Supplement 2, pp. A113. print.
Meeting Info.: 61st Scientific Sessions of the American Diabetes Association Philadelphia, Pennsylvania, USA June 22-26, 2001
ISSN: 0012-1797.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

L11 ANSWER 24 OF 56 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2001:448854 BIOSIS
DOCUMENT NUMBER: PREV200100448854
TITLE: Durable antidiabetic effect of **glyburide/metformin** tablets as second-line therapy for type 2 diabetes.
AUTHOR(S): Blonde, Lawrence (1); Rosenstock, Julio (1); Piper, Beth Ann (1); Henry, David (1)
CORPORATE SOURCE: (1) New Orleans, LA USA
SOURCE: Diabetes, (June, 2001) Vol. 50, No. Supplement 2, pp. A106. print.
Meeting Info.: 61st Scientific Sessions of the American Diabetes Association Philadelphia, Pennsylvania, USA June 22-26, 2001
ISSN: 0012-1797.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

ACCESSION NUMBER: 2001061324 MEDLINE
DOCUMENT NUMBER: 20530757 PubMed ID: 11077467
TITLE: **Glyburide/metformin** (Glucovance) for type 2 diabetes.
AUTHOR: Anonymous
SOURCE: MEDICAL LETTER ON DRUGS AND THERAPEUTICS, (2000 Nov 13) 42 (1092) 105-6.
Journal code: 2985240R. ISSN: 0025-732X.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals
ENTRY MONTH: 200012
ENTRY DATE: Entered STN: 20010322
Last Updated on STN: 20021018
Entered Medline: 20001228

L11 ANSWER 31 OF 56 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2002:580061 BIOSIS
DOCUMENT NUMBER: PREV200200580061
TITLE: Efficacy of **glyburide/metformin** tablets versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled with metformin monotherapy.
AUTHOR(S): Mohideen, P. (1); Klein, E.; Bruce, S. (1)
CORPORATE SOURCE: (1) Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, NJ USA
SOURCE: Diabetologia, (August, 2002) Vol. 45, No. Supplement 2, pp. A 242. print.
Meeting Info.: 38th Annual Meeting of the European Association for the Study of Diabetes (EASD) Budapest, Hungary September 01-05, 2002 European Association for the Study of Diabetes
. ISSN: 0012-186X.
DOCUMENT TYPE: Conference
LANGUAGE: English

L11 ANSWER 32 OF 56 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2001:449039 BIOSIS
DOCUMENT NUMBER: PREV200100449039
TITLE: Combination therapy in type 2 diabetes: Repaglinide/metformin vs **glyburide/metformin**.
AUTHOR(S): Jinagouda, Sujata (1); Schwartz, Sherwyn; Huffman, David; Weinstein, Richard; Davidson, Jaime; Huang, Wonchin; Reinhardt, Rickey
CORPORATE SOURCE: (1) Alhambra, CA USA
SOURCE: Diabetes, (June, 2001) Vol. 50, No. Supplement 2, pp. A439. print.
Meeting Info.: 61st Scientific Sessions of the American Diabetes Association Philadelphia, Pennsylvania, USA June 22-26, 2001
ISSN: 0012-1797.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

L11 ANSWER 33 OF 56 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ACCESSION NUMBER: 2001:449020 BIOSIS
DOCUMENT NUMBER: PREV200100449020
TITLE: 20-month durability of **glyburide/metformin** tablets on glycemic control as initial therapy for type 2 diabetes.
AUTHOR(S): Donovan, Daniel (1); Piper, Beth Ann (1); Park, Jong-Soon

(1)
CORPORATE SOURCE: (1) New York, NY USA
SOURCE: Diabetes, (June, 2001) Vol. 50, No. Supplement 2, pp. A434. print.
Meeting Info.: 61st Scientific Sessions of the American Diabetes Association Philadelphia, Pennsylvania, USA June 22-26, 2001
ISSN: 0012-1797.
DOCUMENT TYPE: Conference
LANGUAGE: English
SUMMARY LANGUAGE: English

L11 ANSWER 34 OF 56 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN
ACCESSION NUMBER: 2002269883 EMBASE
TITLE: Erratum: 'Simultaneous **glyburide/metformin** therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes' (Diabetes, Obesity and Metabolism vol. 4 (3) (201-208)).
SOURCE: Diabetes, Obesity and Metabolism, (2002) 4/4 (286).
ISSN: 1462-8902 CODEN: DOMEF6
COUNTRY: United Kingdom
DOCUMENT TYPE: Journal; Errata
FILE SEGMENT: 003 Endocrinology
LANGUAGE: English

L11 ANSWER 35 OF 56 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V. on STN
ACCESSION NUMBER: 2000404460 EMBASE
TITLE: Transitioning patients with type 2 diabetes to a fixed combination > **glyburide/metformin** tablet.
AUTHOR: Blonde L.; Sandberg M.I.
CORPORATE SOURCE: Dr. L. Blonde, Department of Internal Medicine, Ochsner Diabetes Clinical, Research Unit, 1514 Jefferson Highway, New Orleans, LA 70121, United States. lblonde@Ochsner.org
SOURCE: Diabetes Technology and Therapeutics, (2000) 2/3 (479-480).
Refs: 3
ISSN: 1520-9156 CODEN: DTTHFH
COUNTRY: United States
DOCUMENT TYPE: Journal; Letter
FILE SEGMENT: 003 Endocrinology
037 Drug Literature Index
LANGUAGE: English

L11 ANSWER 43 OF 56 MEDLINE on STN
ACCESSION NUMBER: 2003397110 MEDLINE
DOCUMENT NUMBER: 22815632 PubMed ID: 12934950
TITLE: Using the electronic medical record to enhance the use of combination drugs.
AUTHOR: Wells Brian J; Lobel Keith D; Dickerson Lori M
CORPORATE SOURCE: Department of Family Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.. wellsbj@musc.edu
SOURCE: AMERICAN JOURNAL OF MEDICAL QUALITY, (2003 Jul-Aug) 18 (4) 147-9.
Journal code: 9300756. ISSN: 1062-8606.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200309
ENTRY DATE: Entered STN: 20030826
Last Updated on STN: 20030910
Entered Medline: 20030909

AB The objective of this study was to increase combination drug prescriptions through the use of electronic point-of-care reminders, thereby maintaining quality while decreasing medication costs. The electronic medical record (EMR) was used to identify all patients who were potential candidates for one of the following 3 currently available combination drugs: fluticasone-salmeterol, amlodipine-benazepril, or **glyburide-metformin**. Point-of-care electronic reminders were attached to the medication record of the EMR for each patient, and providers were asked to consider using the available combination medication. Of the patients who had electronic reminders attached to their charts and were seen at the clinic during the study period, 47 of 175 were switched to a combination medication. A cost-savings analysis showed a total annual savings of dollars 6,159.30. Point-of-care reminders are a simple and effective tool for quality-improvement interventions. Combination drugs may play an important role in controlling medication costs.

ACCESSION NUMBER: 2001376630 EMBASE
TITLE: Trends in diabetes care.
AUTHOR: Haveles E.B.
CORPORATE SOURCE: Prof. E.B. Haveles, Old Dominion University, Norfolk, Va, United States
SOURCE: Drug Topics, (1 Oct 2001) 145/19 SUPPL. (29s-36s).
ISSN: 0012-6616 CODEN: DGTNA7
COUNTRY: United States
DOCUMENT TYPE: Journal; General Review
FILE SEGMENT: 003 Endocrinology
006 Internal Medicine
017 Public Health, Social Medicine and Epidemiology
037 Drug Literature Index
LANGUAGE: English
SUMMARY LANGUAGE: English

AB Type 2 diabetes is a common cause of morbidity and mortality that can be prevented or delayed with glycemic control. A sequential approach to treating Type 2 diabetes - initiating monotherapy and moving to combination therapy when monotherapy fails - is widely used and accepted. Sulfonylureas can undoubtedly improve glycemic control with initial therapy and later with the addition of other antidiabetic medications. Metformin is also an option as either monotherapy or combination therapy. Based upon the results of the UKPDS, metformin may be of benefit for significantly obese patients because of the lack of weight gain. In fact, patients may actually lose weight while on metformin. Acarbose may be an option for patients with elevated lipid levels. Acarbose may actually improve the lipid profile by reducing the ratio of LDL-to-HDL cholesterol. The thiazolidinediones have not been shown to have a consistent effect on lipid levels, and these agents cause weight gain. No studies are available that evaluate the effects of repaglinide on lipid levels. There is debate regarding initiating monotherapy or combination therapy as the first-line approach to treating Type 2 diabetes. The ADA continues to recommend sulfonylureas as appropriate monotherapy for initially treating Type 2 diabetes. Eventually, most patients will require some form of combination antidiabetic therapy. Most research involves metformin complemented by a sulfonylurea, though other antidiabetic combinations have been used with success. **Glyburide/metformin** fixed combination is now available, which may improve patient compliance because the patient must remember to take only one "drug," not two separate drugs. However, patients are locked into specific doses, which can create problems. Use of two separate medications in combination affords the clinician the ability to change the dose of one medication at a time and observe for results. Glipizide-GITS, whether as monotherapy or in combination with metformin, is a new option in treating Type 2 diabetes. The formulation is well tolerated, appears to mimic natural insulin release, and is a true once-daily dose form as either first-line or combination therapy. It provides 24-hour control, which is not only convenient but also improves patient compliance. Glipizide-GITS lowers fasting insulin levels more than glyburide and immediate-release glipizide, and long-term data show no weight gain on average and also the possibility that it may actually lower plasma lipid and triglyceride levels. If combination therapy is necessary, the addition of another antidiabetic drug to glipizide-GITS continues to lower HbA(1c) levels. Lastly, efforts to improve patient compliance, continuous monitoring of plasma glucose levels and HbA(1c) levels, and optimizing antidiabetic therapy can improve patient outcomes.

L11 ANSWER 46 OF 56 USPATFULL on STN

ACCESSION NUMBER: 2002216237 MEDLINE
DOCUMENT NUMBER: 21948517 PubMed ID: 11952029
TITLE: Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy.
AUTHOR: Melikian Caron; White T Jeffrey; Vanderplas Ann; Dezii Christopher M; Chang Eunice
CORPORATE SOURCE: Prescription Solutions, Costa Mesa, California 92626, USA.. caron.melikian@phs.com
SOURCE: CLINICAL THERAPEUTICS, (2002 Mar) 24 (3) 460-7.
Journal code: 7706726. ISSN: 0149-2918.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200210
ENTRY DATE: Entered STN: 20020416
Last Updated on STN: 20021002
Entered Medline: 20021001

AB BACKGROUND: Although medication adherence is one of the most important aspects of the management of diabetes mellitus, low rates of adherence have been documented. OBJECTIVE: This study sought to examine medication adherence among patients with diabetes mellitus in a managed care organization who were receiving antidiabetic monotherapy (metformin or glyburide), combination therapy (metformin and glyburide), or fixed-dose combination therapy (**glyburide/metformin**). METHODS: Medication adherence was evaluated through a retrospective database analysis of pharmacy claims. The adherence rate was defined as the sum of the days' supply of oral antidiabetic medication obtained by the patient during the follow-up period divided by the total number of days in the designated follow-up period (180 days). Health plan members were included in the analysis if they had an index pharmacy claim for an oral antidiabetic medication between August 1 and December 31, 2000, were continuously enrolled in the health plan, and were aged > or =18 years. A 6-month pre-index period was used to classify patients as newly treated or previously treated. Patients were grouped according to their medication-use patterns. RESULTS: After adjustment for potential confounding factors, including overall medication burden at index, there were no significant differences in adherence rates among 6502 newly treated patients receiving monotherapy, combination therapy, or fixed-dose combination therapy. Among the 1815 previously treated patients receiving glyburide or metformin monotherapy who required the addition of the alternative agent, resulting in combination therapy, adherence rates were significantly lower (54.0%; 95% CI, 0.52-0.55) than in the 105 patients receiving monotherapy who were switched to fixed-dose combination therapy (77.0%; 95% CI, 0.72-0.82). The 59 previously treated patients receiving combination therapy who were switched to fixed-dose combination therapy had a significant improvement in adherence after the switch (71.0% vs 87.0%; $P < 0.001$). CONCLUSIONS: In a managed care organization, previously treated patients receiving monotherapy with an oral antidiabetic medication who required additional therapy exhibited significantly greater adherence when they were switched to fixed-dose combination therapy compared with combination therapy. Patients receiving combination therapy who were switched to fixed-dose combination therapy exhibited significantly greater adherence after the switch.

ACCESSION NUMBER: 2003397110 MEDLINE
DOCUMENT NUMBER: 22815632 PubMed ID: 12934950
TITLE: Using the electronic medical record to enhance the use of combination drugs.
AUTHOR: Wells Brian J; Lobel Keith D; Dickerson Lori M
CORPORATE SOURCE: Department of Family Medicine, Medical University of South Carolina, Charleston, SC 29425, USA.. wellsbj@musc.edu
SOURCE: AMERICAN JOURNAL OF MEDICAL QUALITY, (2003 Jul-Aug) 18 (4) 147-9.
Journal code: 9300756. ISSN: 1062-8606.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200309
ENTRY DATE: Entered STN: 20030826
Last Updated on STN: 20030910
Entered Medline: 20030909

AB The objective of this study was to increase combination drug prescriptions through the use of electronic point-of-care reminders, thereby maintaining quality while decreasing medication costs. The electronic medical record (EMR) was used to identify all patients who were potential candidates for one of the following 3 currently available combination drugs: fluticasone-salmeterol, amlodipine-benazepril, or **glyburide-metformin**. Point-of-care electronic reminders were attached to the medication record of the EMR for each patient, and providers were asked to consider using the available combination medication. Of the patients who had electronic reminders attached to their charts and were seen at the clinic during the study period, 47 of 175 were switched to a combination medication. A cost-savings analysis showed a total annual savings of dollars 6,159.30. Point-of-care reminders are a simple and effective tool for quality-improvement interventions. Combination drugs may play an important role in controlling medication costs.

L1 ANSWER 1 OF 11 REGISTRY COPYRIGHT 2003 ACS on STN
RN 338752-31-1 REGISTRY
CN Benzamide, 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy-, mixt. with N,N-dimethylimidodicarbonimidic diamide monohydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Imidodicarbonimidic diamide, N,N-dimethyl-, monohydrochloride, mixt. contg. (9CI)
OTHER NAMES:
CN Glucovance
CN **Glyburide-metformin hydrochloride mixt.**
MF C23 H28 Cl N3 O5 S . C4 H11 N5 . Cl H
CI MXS
SR CA
LC STN Files: BIOSIS, CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 10238-21-8
CMF C23 H28 Cl N3 O5 S



CM 2

CRN 1115-70-4 (657-24-9)
CMF C4 H11 N5 . Cl H



● HCl

8 REFERENCES IN FILE CA (1937 TO DATE)
8 REFERENCES IN FILE CAPLUS (1937 TO DATE)

L1 ANSWER 2 OF 11 REGISTRY COPYRIGHT 2003 ACS on STN
RN 338752-30-0 REGISTRY
CN Benzamide, 5-chloro-N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-2-methoxy-, mixt. with N,N-dimethylimidodicarbonimidic diamide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Imidodicarbonimidic diamide, N,N-dimethyl-, mixt. contg. (9CI)
OTHER NAMES:
CN **Glyburide-metformin mixt.**
MF C23 H28 Cl N3 O5 S . C4 H11 N5
CI MXS

SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL

CM 1

CRN 10238-21-8
CMF C23 H28 Cl N3 O5 S



CM 2

CRN 657-24-9
CMF C4 H11 N5



4 REFERENCES IN FILE CA (1937 TO DATE)
4 REFERENCES IN FILE CAPLUS (1937 TO DATE)

L1 ANSWER 3 OF 11 REGISTRY COPYRIGHT 2003 ACS on STN
RN 88159-36-8 REGISTRY
CN Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl-, monosodium salt (9CI) (CA INDEX NAME)
OTHER NAMES:
CN **Sodium glipizide**
MF C21 H27 N5 O4 S . Na
LC STN Files: CA, CAPLUS, DRUGPAT
CRN (29094-61-9)



1 REFERENCES IN FILE CA (1937 TO DATE)
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

L1 ANSWER 4 OF 11 REGISTRY COPYRIGHT 2003 ACS on STN
RN 58840-24-7 REGISTRY
CN 4-Pyrimidinecarboxylic acid, 1,2,3,6-tetrahydro-2,6-dioxo-, compd. with

N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Imidodicarbonimidic diamide, N,N-dimethyl-, mono(1,2,3,6-tetrahydro-2,6-dioxo-4-pyrimidinecarboxylate) (9CI)
OTHER NAMES:
CN **Metformin orotate**
MF C5 H4 N2 O4 . C4 H11 N5
LC STN Files: BEILSTEIN*, CA, CAPLUS, RTECS*
(*File contains numerically searchable property data)

CM 1

CRN 657-24-9
CMF C4 H11 N5



CM 2

CRN 65-86-1
CMF C5 H4 N2 O4



1 REFERENCES IN FILE CA (1937 TO DATE).
1 REFERENCES IN FILE CAPLUS (1937 TO DATE)

L1 ANSWER 5 OF 11 REGISTRY COPYRIGHT 2003 ACS on STN
RN 53950-18-8 REGISTRY
CN Propanoic acid, 2-(4-chlorophenoxy)-2-methyl-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Imidodicarbonimidic diamide, N,N-dimethyl-, mono[2-(4-chlorophenoxy)-2-methylpropanoate] (9CI)
OTHER NAMES:
CN ANP 4324
CN **Metformin clofibrate**
MF C10 H11 Cl O3 . C4 H11 N5
LC STN Files: BEILSTEIN*, BIOSIS, CA, CAPLUS, IFICDB, IFIPAT, IFIUDB
(*File contains numerically searchable property data)

CM 1

CRN 882-09-7
CMF C10 H11 Cl O3



CM 2

CRN 657-24-9
CMF C4 H11 N5



4 REFERENCES IN FILE CA (1937 TO DATE)
4 REFERENCES IN FILE CAPLUS (1937 TO DATE)

L1 ANSWER 6 OF 11 REGISTRY COPYRIGHT 2003 ACS on STN
RN 51394-30-0 REGISTRY
CN Benzenesulfonamide, 4-chloro-N-[(propylamino)carbonyl]-, mixt. with N,N-dimethylimidodicarbonimidic diamide (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Imidodicarbonimidic diamide, N,N-dimethyl-, mixt. contg. (9CI)
OTHER NAMES:
CN Chlorpropamide-1,1-dimethylbiguanide mixt.
CN **Chlorpropamide-metformin mixt.**
CN Obinese
MF C10 H13 Cl N2 O3 S . C4 H11 N5
CI MXS
LC STN Files: BEILSTEIN*, CA, CAPLUS, EMBASE
(*File contains numerically searchable property data)

CM 1

CRN 657-24-9
CMF C4 H11 N5



CM 2

CRN 94-20-2
CMF C10 H13 Cl N2 O3 S





2 REFERENCES IN FILE CA (1937 TO DATE)
2 REFERENCES IN FILE CAPLUS (1937 TO DATE)

L1 ANSWER 7 OF 11 REGISTRY COPYRIGHT 2003 ACS on STN
RN 38950-16-2 REGISTRY
CN Benzenesulfonamide, N-[(butylamino)carbonyl]-4-methyl-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:1) (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Biguanide, 1,1-dimethyl-, compd. with 1-butyl-3-p-tolylsulfonylurea (6CI)
CN Imidodicarbonimidic diamide, N,N-dimethyl-, compd. with N-[(butylamino)carbonyl]-4-methylbenzenesulfonamide (1:1) (9CI)
CN Urea, 1-butyl-3-(p-tolylsulfonyl)-, compd. with 1,1-dimethylbiguanide (7CI)
OTHER NAMES:
CN 1-Butyl-3-(p-tolylsulfonyl)urea and 1,1-dimethylbiguanide adduct
CN **Metformin tolbutamide salt**
MF C12 H18 N2 O3 S . C4 H11 N5
LC STN Files: BEILSTEIN*, CA, CAOLD, CAPLUS, TOXCENTER
(*File contains numerically searchable property data)

CM 1

CRN 657-24-9
CMF C4 H11 N5



CM 2

CRN 64-77-7
CMF C12 H18 N2 O3 S



4 REFERENCES IN FILE CA (1937 TO DATE)
4 REFERENCES IN FILE CAPLUS (1937 TO DATE)
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L1 ANSWER 8 OF 11 REGISTRY COPYRIGHT 2003 ACS on STN
RN 34461-22-8 REGISTRY
CN 2-Naphthalenecarboxylic acid, 4,4'-methylenebis[3-hydroxy-, compd. with N,N-dimethylimidodicarbonimidic diamide (1:2) (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:
CN 2-Naphthoic acid, 4,4'-methylenebis[3-hydroxy-, compd. with 1,1-dimethylbiguanide (1:2) (8CI)
CN Imidodicarbonimidic diamide, N,N-dimethyl-, 4,4'-methylenebis[3-hydroxy-2-naphthalenecarboxylate] (2:1) (9CI)
OTHER NAMES:
CN **Metformin pamoate**
MF C23 H16 O6 . 2 C4 H11 N5
LC STN Files: BIOTECHNO, CA, CAPLUS, CHEMLIST, CSCHEM, EMBASE, MRCK*, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)

CM 1

CRN 657-24-9
CMF C4 H11 N5



CM 2

CRN 130-85-8
CMF C23 H16 O6



5 REFERENCES IN FILE CA (1937 TO DATE)
5 REFERENCES IN FILE CAPLUS (1937 TO DATE)

L1 ANSWER 9 OF 11 REGISTRY COPYRIGHT 2003 ACS on STN
RN 29094-61-9 REGISTRY
CN Pyrazinecarboxamide, N-[2-[4-[[[(cyclohexylamino)carbonyl]amino]sulfonyl]phenyl]ethyl]-5-methyl- (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Urea, 1-cyclohexyl-3-[[p-[2-(5-methylpyrazinecarboxamido)ethyl]phenyl]sulfonyl]- (8CI)
OTHER NAMES:
CN Aldiab
CN CP 28720
CN Digrin
CN Dipazide
CN Glibenese
CN Glibetin
CN Glican
CN Glidiab

CN Glipid
CN **Glipizide**
CN Gluco-Rite
CN Glucolip
CN Glucotrol
CN Glucotrol Xl
CN Glucozide
CN Glupitel
CN Glupizide
CN Glyde
CN Glydiazinamide
CN Glynase
CN K 4024
CN Melizide
CN Mindiab
CN Minidab
CN Minidiab
CN Minodiab
CN N-(4-[.beta.-(5-Methylpyrazine-2-carboxamido)ethyl]benzenesulfonyl)-N'-cyclohexylurea
CN Napizide
CN Ozidia
CN Sucrazide
CN TK 1320
FS 3D CONCORD
DR 172964-66-8, 29094-66-4, 38777-27-4
MF C21 H27 N5 O4 S
CI COM
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGPAT, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK*, PHAR, PHARMASEARCH, PROMT, RTECS*, SPECINFO, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: EINECS**, WHO
(**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

592 REFERENCES IN FILE CA (1937 TO DATE)
3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
594 REFERENCES IN FILE CAPLUS (1937 TO DATE)

L1 ANSWER 10 OF 11 REGISTRY COPYRIGHT 2003 ACS on STN
RN 1115-70-4 REGISTRY
CN Imidodicarbonimidic diamide, N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Biguanide, 1,1-dimethyl-, hydrochloride (6CI)
CN Biguanide, 1,1-dimethyl-, monohydrochloride (8CI)
OTHER NAMES:
CN 1,1-Dimethylbiguanide hydrochloride
CN Apophage
CN Benofomin
CN Dabex

CN Denkaform
CN Dextin
CN Diabefagos
CN Diabetmin
CN Diabetosan
CN Diabex
CN Diaformin
CN Dialon
CN Diformin
CN Diformin Retard
CN Dimefor
CN Fornidd
CN Geamet
CN Glucaminol
CN Glucofago
CN Glucoform
CN Glucomet
CN Glucomin
CN Glucomine
CN Gluconil
CN Glucophage
CN Glucophage 850
CN Glucophage Forte
CN Glucophage Retard
CN Glucophage-Mite
CN Gludepatic
CN Glufor
CN Gluformin
CN Glumeformin
CN Glumin
CN Glupermin
CN Glyceriphage
CN Glyciphage
CN Glycon
CN Glyformin
CN LA 6023
CN Meguan
CN Metforal
CN **Metformin hydrochloride**
CN Metomin
CN Miformin
CN N,N-Dimethylbiguanide hydrochloride
CN N1,N1-Dimethylbiguanide hydrochloride
CN Orabet
ADDITIONAL NAMES NOT AVAILABLE IN THIS FORMAT - Use FCN, FIDE, or ALL for DISPLAY
DR 56258-19-6, 15537-72-1, 144377-16-2
MF C4 H11 N5 . Cl H
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, DIOGENES, DRUGUPDATES, EMBASE, GMELIN*, HSDB*, IFICDB, IFIPAT, IFIUDB, IPA, MRCK*, MSDS-OHS, PHAR, PHARMASEARCH, PROMT, RTECS*, TOXCENTER, ULIDAT, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**
(**Enter CHEMLIST File for up-to-date regulatory information)
CRN (657-24-9)

19 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

L8 ANSWER 150 OF 183 USPATFULL on STN
ACCESSION NUMBER: 2003:24185 USPATFULL
TITLE: Combination therapy for type II diabetes or Syndrome X
INVENTOR(S): Gwynne, John Thomas, Doylestown, PA, UNITED STATES
Vitou, Philippe John Robert, Paris, FRANCE
Randazzo, Bruce Paul, Rydal, PA, UNITED STATES
PATENT ASSIGNEE(S): Wyeth, Madison, NJ (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003018028	A1	20030123	
APPLICATION INFO.:	US 2002-163707	A1	20020606	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-296502P	20010607	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Arnold S. Milowsky, 5 Giralda Farms, Madison, NJ, 07940
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 1108
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods of using a pharmacological combination of a biguanide agents, such as metformin, and one or more PTPase inhibiting agents and, optionally, one or more sulfonlylurea agents, including glyburide, glyburide, **glipizide**, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents.

[redacted]

L8 ANSWER 162 OF 183 USPATFULL on STN
ACCESSION NUMBER: 1999:81839 USPATFULL
TITLE: Methods for use of cryptolepine analogs with hypoglycemic activity
INVENTOR(S): Bierer, Donald E., Daly City, CA, United States
PATENT ASSIGNEE(S): Shaman Pharmaceuticals, Inc., South San Francisco, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5925647		19990720
APPLICATION INFO.:	US 1997-955320		19971020 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-484424, filed on 7 Jun 1995, now patented, Pat. No. US 5681958
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Schenkman, Leonard
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1,4
NUMBER OF DRAWINGS: 9 Drawing Figure(s); 9 Drawing Page(s)
LINE COUNT: 3932
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel cryptolepine analogs useful as hypoglycemic agents and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes, and a method for their synthesis are described. As hypoglycemic agents, the novel cryptolepine analogs are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).

L19 ANSWER 1 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2002:315117 USPATFULL
TITLE: ANTIDIABETIC FORMULATION AND METHOD
INVENTOR(S): PIPER, BETH ANNE, HOPEWELL, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002177602	A1	20021128	
	US 6586438	B2	20030701	
APPLICATION INFO.:	US 1999-432465	A1	19991103	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
NUMBER OF CLAIMS: 76
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1927
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A low dose antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes in drug naive patients, which includes a combination of **metformin** (employed in a reduced amount (less than 800 mg **metformin** per day) compared to that employed in generally accepted medical practice) and at least one other antidiabetic agent such as a sulfonyl urea, for example, glyburide, which combination provides at least about substantially equivalent efficacy in treating diabetes in drug naive patients, as do antidiabetic formulations containing **metformin** employed in dosages prescribed in generally accepted medical practice for first line therapy in treating diabetes, but with substantially reduced side effects, such as hypoglycemia and/or gastrointestinal distress. A method for treating diabetes in drug naive human patients is also provided employing the above formulation to reduce insulin resistance and/or post-prandial glucose excursion and/or hemoglobin 1Ac, and/or increase post-prandial insulin, thereby treating the diabetes.

L19 ANSWER 2 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2000:24678 USPATFULL
TITLE: Salts of **metformin** and method
INVENTOR(S): Timmins, Peter, Merseyside, United Kingdom
Winter, William J., Lebanon, NJ, United States
Srivastava, Sushil K., Dayton, NJ, United States
Bretnall, Alison E., Chester, United Kingdom
Wei, Chenkou, Princeton Junction, NJ, United States
Powers, Gerald L., North Brunswick, NJ, United States
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6031004		20000229
APPLICATION INFO.:	US 1999-262526		19990304 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1997-986586, filed on 8 Dec 1997
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Fay, Zohreh
LEGAL REPRESENTATIVE: Rodney, Burton
NUMBER OF CLAIMS: 24
EXEMPLARY CLAIM: 1
LINE COUNT: 651
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Novel salts of the antidiabetic agent **metformin** acre provided which are **metformin** salts of dibasic acids (2:1 molar ratio), preferably **metformin** (2:1) fumarate and **metformin** (2:1) succinate, which may be employed alone or in combination with another antihyperglycemic agent such as glyburide, for treating diabetes. A method for treating diabetes employing the novel **metformin** salt by itself or in combination with another antidiabetic agent is also provided.

ACCESSION NUMBER: 2003:112605 USPATFULL
TITLE: Formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
INVENTOR(S): Richardson, Kenneth T., Anchorage, AK, UNITED STATES
Pearson, Don C., Lakewood, WA, UNITED STATES
PATENT ASSIGNEE(S): ChronoRX LLC, Anchorage, AK (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003077335	A1	20030424	
APPLICATION INFO.:	US 2001-33730	A1	20011102	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-245471P	20001103	(60)
	US 2000-245950P	20001103	(60)
	US 2000-256033P	20001213	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 104
EXEMPLARY CLAIM: 1
LINE COUNT: 4450
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The compositions and dosage forms of the invention are clinically useful as methods for increasing the effectiveness, efficiency and safety of biguanides (**metformin**) and/or sulfonylureas in the prevention and treatment of insulin resistance and diabetes mellitus, alone or in combination, as a nutrient for humans. The carefully chosen active ingredients of the invention are designed in a modular fashion to prevent and rectify adverse events associated with insulin resistance syndrome and diabetes mellitus, and with the clinical use of biguanides (**metformin**) and/or the sulfonylureas. These modules are: (1) Mitochondrial Metabolic Group, (2) Plasma and Mitochondrial Membrane Integrity Group, (3) Nocturnal Group and, (4) Insulin Alternative Group. When used in concert with a biguanide, a sulfonylurea or with a combination of both, the invention will broaden the clinical usefulness of these drugs. The invention will retard the progression of insulin resistance to type 2 diabetes, and reduce the serious microvascular and macrovascular complications commonly associated with insulin resistance syndrome and diabetes mellitus.

L19 ANSWER 6 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1988:156419 HCAPLUS
DOCUMENT NUMBER: 108:156419
TITLE: Preparation and evaluation of **metformin** hydrochloride controlled-release **tablets**
AUTHOR(S): Abdallah, O. Y.; Boraie, N. A.; Naggar, V. F.
CORPORATE SOURCE: Fac. Pharm., Univ. Alexandria, Alexandria, Egypt
SOURCE: S.T.P. Pharma (1988), 4(1), 15-20
CODEN: STPPEF; ISSN: 0758-6922
DOCUMENT TYPE: Journal
LANGUAGE: English

AB **Metformin**-HCl **tablets** intended for controlled release were prepd. using Me **cellulose**, Et **cellulose**, **cellulose** acetate, **cellulose** triacetate and Eudragit RS, RL or S. The techniques employed were direct compression, wet granulation or copptn. followed by compression. The release properties of the resulting **tablets** were evaluated in 0.1N HCl and phosphate buffer (pH 6.8). The wet granulation technique could be applied successfully with Et **cellulose**, Eudragit RS and Eudragit RL. Me **cellulose** in a matrix prepd. by copptn. showed great promise as a retardant for release. The effect of varying the relative proportion of this polymer was also studied. The dissoln. properties of 4 com. regular **tablets** and a sustained-release **tablet** were also detd. The release patterns were examd. from the standpoint of a diffusion-controlled process and that of 1st-order kinetics process.

L19 ANSWER 7 OF 256 USPATFULL on STN

ACCESSION NUMBER:	2003:123367 USPATFULL
TITLE:	Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
INVENTOR(S):	Gatlin, Marjorie Regan, Hoboken, NJ, United States Ball, Michele Ann, Morris Plains, NJ, United States Mannion, Richard Owen, Mount Arlington, NJ, United States Karnachi, Anees Abdulquadar, Hillsborough, NJ, United States Guitard, Christiane, Hegenheim, FRANCE Allison, Malcolm, Basel, SWITZERLAND
PATENT ASSIGNEE(S):	Novartis AG, Basel, SWITZERLAND (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6559188	B1	20030506	
APPLICATION INFO.:	US 2000-663264		20000915	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2000-304196P	20000407	(60)
	US 2000-240918P	20000309	(60)
	US 1999-242911P	19990917	(60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	GRANTED
PRIMARY EXAMINER:	Weddington, Kevin E.
LEGAL REPRESENTATIVE:	Thallemer, John D.
NUMBER OF CLAIMS:	11
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT:	2176

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a combination, such as a combined preparation or pharmaceutical composition, respectively, which comprises nateglinide (I) ##STR1##

or repaglinide and at least one other antidiabetic compound selected from the group consisting of thiazolidinedione derivatives (glitazones), sulfonyl urea derivatives and **metformin** for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of diseases, especially metabolic disorders and in particular type 2 diabetes and diseases and conditions associated with diabetes; to a composition, respectively, which comprises nateglinide and a pharmaceutically acceptable carrier and to a process of making such composition; the use of such combination or composition for the preparation of a medicament for the prevention, delay of progression or treatment of metabolic disorders; a method of prevention, delay of progression or treatment of diseases in warm-blooded animals; the use of such combination or composition for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight; and to a method of improving the bodily appearance of a warm-blooded animal.

L19 ANSWER 10 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:636165 HCAPLUS
DOCUMENT NUMBER: 133:227811
TITLE: Directly compressed **metformin** hydrochloride **tablets**
INVENTOR(S): Kumar, Vijai
PATENT ASSIGNEE(S): Pharmalogix, Inc., USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6117451	A	20000912	US 1998-139361	19980825

PRIORITY APPLN. INFO.: US 1998-139361 19980825

AB **Metformin** Hydrochloride (herein referred to as **metformin** HCl) that may be 98.5%-100% pure is a high dose drug capable of being directly compressed with specific excipients into **tablets** having desired hardness, disintegrating ability, and acceptable dissoln. characteristics. **Metformin** HCl is not inherently compressible and thus presents formulation problems. Excipients used in the formulation enhance the flow and compaction properties of the drug and tableting mix. Optimal flow contributes to uniform die fill and wt. control. The binder used ensures sufficient cohesive properties that allow **metformin** HCl to be compressed using the direct compression method. The **tablets** produced provide an acceptable in-vitro dissoln. profile. A directly compressed **tablet** contained **metformin** HCl 500, microcryst. **cellulose** 36.85, hydroxypropyl Me **cellulose** 77.9, Povidone 26.8, colloidal silica 3.25, and Mg stearate 5.2 mg.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 13 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:866782 HCAPLUS
DOCUMENT NUMBER: 137:358144
TITLE: Fast-release **tablets** containing **metformin** hydrochloride
INVENTOR(S): Matsui, Tadashi; Yuasa, Shuichiro
PATENT ASSIGNEE(S): Toa Eiyo, Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2002326927	A2	20021115	JP 2001-136873	20010508

PRIORITY APPLN. INFO.: JP 2001-136873 20010508

AB The title **tablets** comprise (1) 85-97.5 % **metformin** hydrochloride (I) and (2) 2-10 % hydroxypropyl **cellulose** which shows 2-10 mPas viscosity as a 2 % aq. soln. at 20.degree.. The **tablets** release .gtoreq. 85 % I in 15 min when tested according to Japanese Pharmacopeia XIII dissoln. test method. For example, a **tablet** contained I 250, hydroxypropyl **cellulose** (HPC SSL) 17.3, talc 1.35, and Mg stearate 1.35 mg.

L19 ANSWER 14 OF 256 USPATFULL on STN

ACCESSION NUMBER:	2002:126046 USPATFULL
TITLE:	Controlled release oral **tablet** having a unitary core
INVENTOR(S):	Cheng, Xiu Xiu, Davie, FL, UNITED STATES Chen, Chih-Ming, Davie, FL, UNITED STATES Jan, Steve, Coral Springs, FL, UNITED STATES Chou, Joseph, Coral Springs, FL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002064556	A1	20020530
	US 6495162	B2	20021217
APPLICATION INFO.:	US 2001-16556	A1	20011101 (10)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-594637, filed on 15 Jun 2000, PENDING
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Martin P. Endres, Esq., HEDMAN & COSTIGAN, PC., 1185 Avenue of the Americas, New York, NY, 10036
NUMBER OF CLAIMS:	30
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	8 Drawing Page(s)
LINE COUNT:	609

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A controlled release antihyperglycemic **tablet** that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane **coating** the core and at least one passageway in the membrane.

L19 ANSWER 15 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2000:101892 USPATFULL
TITLE: Controlled release oral **tablet** having a unitary core
INVENTOR(S): Cheng, Xiu Xiu, Davie, FL, United States
Chen, Chih-Ming, Davie, FL, United States
Jan, Steve, Coral Springs, FL, United States
Chou, Joseph, Coral Springs, FL, United States
PATENT ASSIGNEE(S): Andrx Pharmaceuticals, Inc., Fort Lauderdale, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6099859		20000808	
APPLICATION INFO.:	US 1998-45330		19980320	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Benston, Jr., William E.
LEGAL REPRESENTATIVE: Hedman, Gibson & Costigan, P.C.
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 8 Drawing Figure(s); 8 Drawing Page(s)
LINE COUNT: 628
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A controlled release antihyperglycemic **tablet** that does not contain an expanding polymer and comprising a core containing the antihyperglycemic drug, a semipermeable membrane **coating** the core and at least one passageway in the membrane.

L19 ANSWER 16 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:380381 HCAPLUS
DOCUMENT NUMBER: 134:371803
TITLE: Antidiabetic compositions containing thiazolidinedione derivatives and **metformin**
INVENTOR(S): Lewis, Karen; Lillott, Nicola Jayne; Mackenzie, Donald Colin
PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
SOURCE: PCT Int. Appl., 10 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001035940	A2	20010525	WO 2000-GB4363	20001116
WO 2001035940	A3	20020321		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1231917	A2	20020821	EP 2000-976151	20001116
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003514011	T2	20030415	JP 2001-537933	20001116

PRIORITY APPLN. INFO.:
GB 1999-27121 A 19991116
GB 2000-13238 A 20000531
WO 2000-GB4363 W 20001116

AB A pharmaceutical compn. comprises a thiazolidinedione, **metformin** .cntdot.HCl, and a pharmaceutically acceptable carrier, wherein the thiazolidinedione is formulated upon the surface of the **metformin** .cntdot.HCl. A **tablet** was formulated contg. **metformin** .cntdot.HCl 500, PVP 15, and Mg stearate 5 mg. A film coated **tablet** contained the above **tablet** 520, **Opadry** barrier coat 5.20, **Opadry coating** suspension contg. 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione (I) 15.90 (equiv. to 4 mg I), and **Opadry** I seal coat 10.80 mg.

L19 ANSWER 17 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:547478 HCAPLUS
DOCUMENT NUMBER: 133:155443
TITLE: **Metformin** formulations and method for treating intermittent claudication employing same
INVENTOR(S): Rogosky, Karen M.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S., 4 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6100300	A	20000808	US 1998-67565	19980428

PRIORITY APPLN. INFO.: US 1998-67565 19980428

AB Novel **metformin** formulations are provided which include **metformin** or **metformin** salts preferably the hydrochloride salt in doses below that employed for treating diabetes such as **metformin** in daily amts. of 400 mg or below. A method for treating peripheral vascular disease including intermittent claudication employing such **metformin** formulations is also provided. A **tablet** contained **metformin**.cntdot.HCl 50, microcryst. **cellulose** 8, Na **croscarmellose** 4.5, Povidone 1.5, and Mg stearate 0.8 mg.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

CCESSION NUMBER: 1998:628926 HCAPLUS
DOCUMENT NUMBER: 130:57084
TITLE: Improvement of quality of **metformin** hydrochloride **tablets** by superdisintegrants
AUTHOR(S): Wang, Xueliang; Fang, Xiaoling; Yang, Min; Zhang, Jin
CORPORATE SOURCE: Shanghai Sifu Pharmaceutical Company, Shanghai, 201106, Peop. Rep. China
SOURCE: Zhongguo Yaoxue Zazhi (Beijing) (1998), 33(7), 434-435
CODEN: ZYZAEU; ISSN: 1001-2494
PUBLISHER: Zhongguo Yaoxuehui
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB The improvement of quality of **metformin** hydrochloride **tablets** in different formulations was studied. Six formulations of **metformin** hydrochloride **tablets** were designed and prepd. with microcryst. **cellulose**, L-HPC and three superdisintegrants (crosslinking PVP, crosslinking CMC-Na, CMS-Na) resp. The disintegration time, dissoln. rate, hardness (crushing strength) of **tablets**, and the granules properties were detd. and compared. The hardness of the 6 formulations were all greater than 8 kg. The disintegration time of the **tablets** contg. cross- linking PVP and crosslinking CMC-Na resp. were shorter than 3 min with dissoln. within 5 min. 95% Of drugs released from formulations contg. L-HPC and microcryst. **cellulose** within 10 min. The quality of **metformin** hydrochloride **tablets** might be significantly improved by using 4% of superdisintegrants, such as crosslinking PVP, crosslinking CMC-Na, L-HPC and CMS-Na.

L19 ANSWER 22 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:376620 HCAPLUS
DOCUMENT NUMBER: 138:374198
TITLE: Controlled-release **metformin tablets**
INVENTOR(S): Chawla, Manish; Raghuvanshi, Rajeev S.; Rampal, Ashok
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039527	A1	20030515	WO 2002-IB4647	20021106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003104059	A1	20030605	US 2002-289070	20021106

PRIORITY APPLN. INFO.: IN 2001-DE1134 A 20011106

AB Controlled-release **metformin tablets** were prepd. using a combination of nonionic and anionic hydrophilic polymers, wherein the total hydrophilic polymer concn. is at least about 16% by wt. of the compn. **Tablets** were prepd. contg. **metformin**-HCl 68.0, Na CM-**cellulose** 4.0, HPMC 12.0, binder 1.6, diluent 13.2, lubricant 0.6, and glidant 0.6 % wt./wt.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2000:68154 HCAPLUS
DOCUMENT NUMBER: 132:113105
TITLE: **Tablets** comprising a combination of **metformin** and glibenclamide
INVENTOR(S): Bonhomme, Yves; Nicholson, Geoffrey
PATENT ASSIGNEE(S): LIPHA, Lyonnaise Industrielle Pharmaceutique, Fr.
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 974356	A1	20000126	EP 1998-401781	19980715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2303537	AA	20000127	CA 1999-2303537	19990712
WO 2000003742	A2	20000127	WO 1999-EP5571	19990712
WO 2000003742	A3	20000420		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9954179	A1	20000207	AU 1999-54179	19990712
AU 753604	B2	20021024		
EP 1011684	A2	20000628	EP 1999-940114	19990712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9906600	A	20000718	BR 1999-6600	19990712
JP 2002520371	T2	20020709	JP 2000-559876	19990712
NZ 503248	A	20020927	NZ 1999-503248	19990712
US 6303146	B1	20011016	US 1999-353141	19990714
ZA 2000001159	A	20010531	ZA 2000-1159	20000307

PRIORITY APPLN. INFO.: EP 1998-401781 A 19980715
WO 1999-EP5571 W 19990712

AB The present invention relates to a **tablet** comprising a combination of **metformin** and glibenclamide in which the size of the glibenclamide is such that at most 10 % of the particles are less than 2 .mu.m and at most 10% of the particles are greater than 60 .mu.m. The selection of a specific size fraction of glibenclamide enables the prodn. of a combination **tablet** exhibiting comparable glibenclamide bioavailability to the co-administered **tablets**, when judged by the AUC in vivo anal. PVP 66.6 g, **metformin**.cntdot.HCl 1500 g, glibenclamide (10-90 % size range 2-60 .mu.m) 7.5 g, **croscarmellose** Na 42 g, microcryst. **cellulose** 284.4 g, and water 246 g were mixed and granulated. The granules were extruded through a 1 mm mesh and further mixed with microcryst. **cellulose** and Mg stearate. The granule mix was compressed to **tablets**, which were coated with a 2 % hydroxypropyl Me **cellulose**.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 24 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:280470 HCAPLUS
DOCUMENT NUMBER: 133:168245
TITLE: Study on HPMC matrix **tablets** of **metformin** hydrochloride
AUTHOR(S): Xu, Qun-Wei; Hao, Qing; Zhu, Xiang-Jun
CORPORATE SOURCE: Jiangsu Institute of Materia Medica, Nanjing, 210009, Peop. Rep. China
SOURCE: Zhongguo Yaoke Daxue Xuebao (2000), 31(1), 15-17
CODEN: ZHYXE9; ISSN: 1000-5048
PUBLISHER: Zhongguo Yaoke Daxue
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB The HPMC matrix **tablets** of **metformin** hydrochloride (MH) were compressed by using wet method. The effect of the amt., viscosity of hydroxypropyl methylcellulose and species of bonding agent such as Et **cellulose**, alc., Eudragit III on the MH release rate from matrix **tablets** was investigated. The exptl. design using orthogonal table has shown that the amt. and species of bonding agent were affected in the MH release rate from matrix **tablets** and the viscosity of HPMC was not significant.

L19 ANSWER 21 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:628926 HCAPLUS
DOCUMENT NUMBER: 130:57084
TITLE: Improvement of quality of **metformin** hydrochloride **tablets** by superdisintegrants
AUTHOR(S): Wang, Xueliang; Fang, Xiaoling; Yang, Min; Zhang, Jin
CORPORATE SOURCE: Shanghai Sifu Pharmaceutical Company, Shanghai, 201106, Peop. Rep. China
SOURCE: Zhongguo Yaoxue Zazhi (Beijing) (1998), 33(7), 434-435
CODEN: ZYZAEU; ISSN: 1001-2494
PUBLISHER: Zhongguo Yaoxuehui
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB The improvement of quality of **metformin** hydrochloride **tablets** in different formulations was studied. Six formulations of **metformin** hydrochloride **tablets** were designed and prepd. with microcryst. **cellulose**, L-HPC and three superdisintegrants (crosslinking PVP, crosslinking CMC-Na, CMS-Na) resp. The disintegration time, dissoln. rate, hardness (crushing strength) of **tablets**, and the granules properties were detd. and compared. The hardness of the 6 formulations were all greater than 8 kg. The disintegration time of the **tablets** contg. cross- linking PVP and crosslinking CMC-Na resp. were shorter than 3 min with dissoln. within 5 min. 95% Of drugs released from formulations contg. L-HPC and microcryst. **cellulose** within 10 min. The quality of **metformin** hydrochloride **tablets** might be significantly improved by using 4% of superdisintegrants, such as crosslinking PVP, crosslinking CMC-Na, L-HPC and CMS-Na.

L19 ANSWER 22 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:376620 HCAPLUS
DOCUMENT NUMBER: 138:374198
TITLE: Controlled-release **metformin tablets**
INVENTOR(S): Chawla, Manish; Raghuvanshi, Rajeev S.; Rampal, Ashok
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003039527	A1	20030515	WO 2002-IB4647	20021106

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003104059	A1	20030605	US 2002-289070	20021106

PRIORITY APPLN. INFO.: IN 2001-DE1134 A 20011106

AB Controlled-release **metformin tablets** were prepd. using a combination of nonionic and anionic hydrophilic polymers, wherein the total hydrophilic polymer concn. is at least about 16% by wt. of the compn. **Tablets** were prepd. contg. **metformin**-HCl 68.0, Na CM-**cellulose** 4.0, HPMC 12.0, binder 1.6, diluent 13.2, lubricant 0.6, and glidant 0.6 % wt./wt.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 23 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:68154 HCAPLUS
DOCUMENT NUMBER: 132:113105
TITLE: **Tablets** comprising a combination of **metformin** and glibenclamide
INVENTOR(S): Bonhomme, Yves; Nicholson, Geoffrey
PATENT ASSIGNEE(S): LIPHA, Lyonnaise Industrielle Pharmaceutique, Fr.
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 974356	A1	20000126	EP 1998-401781	19980715
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2303537	AA	20000127	CA 1999-2303537	19990712
WO 2000003742	A2	20000127	WO 1999-EP5571	19990712
WO 2000003742	A3	20000420		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9954179	A1	20000207	AU 1999-54179	19990712
AU 753604	B2	20021024		
EP 1011684	A2	20000628	EP 1999-940114	19990712
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 9906600	A	20000718	BR 1999-6600	19990712
JP 2002520371	T2	20020709	JP 2000-559876	19990712
NZ 503248	A	20020927	NZ 1999-503248	19990712
US 6303146	B1	20011016	US 1999-353141	19990714
ZA 2000001159	A	20010531	ZA 2000-1159	20000307

PRIORITY APPLN. INFO.: EP 1998-401781 A 19980715
WO 1999-EP5571 W 19990712

AB The present invention relates to a **tablet** comprising a combination of **metformin** and glibenclamide in which the size of the glibenclamide is such that at most 10 % of the particles are less than 2 .mu.m and at most 10% of the particles are greater than 60 .mu.m. The selection of a specific size fraction of glibenclamide enables the prodn. of a combination **tablet** exhibiting comparable glibenclamide bioavailability to the co-administered **tablets**, when judged by the AUC in vivo anal. PVP 66.6 g, **metformin**.cntdot.HCl 1500 g, glibenclamide (10-90 % size range 2-60 .mu.m) 7.5 g, **croscarmellose** Na 42 g, microcryst. **cellulose** 284.4 g, and water 246 g were mixed and granulated. The granules were extruded through a 1 mm mesh and further mixed with microcryst. **cellulose** and Mg stearate. The granule mix was compressed to **tablets**, which were coated with a 2 % hydroxypropyl Me **cellulose**.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 24 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2000:280470 HCAPLUS
DOCUMENT NUMBER: 133:168245
TITLE: Study on HPMC matrix **tablets** of **metformin** hydrochloride
AUTHOR(S): Xu, Qun-Wei; Hao, Qing; Zhu, Xiang-Jun
CORPORATE SOURCE: Jiangsu Institute of Materia Medica, Nanjing, 210009, Peop. Rep. China
SOURCE: Zhongguo Yaoke Daxue Xuebao (2000), 31(1), 15-17
CODEN: ZHYXE9; ISSN: 1000-5048
PUBLISHER: Zhongguo Yaoke Daxue
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
AB The HPMC matrix **tablets** of **metformin** hydrochloride (MH) were compressed by using wet method. The effect of the amt., viscosity of hydroxypropyl methylcellulose and species of bonding agent such as Et **cellulose**, alc., Eudragit III on the MH release rate from matrix **tablets** was investigated. The exptl. design using orthogonal table has shown that the amt. and species of bonding agent were affected in the MH release rate from matrix **tablets** and the viscosity of HPMC was not significant.

L19 ANSWER 25 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2002:72923 USPATFULL
TITLE: Liquid formulation of **metformin**
INVENTOR(S): Chandran, Ravi, Bolton Landing, NY, UNITED STATES
Gogia, Ashish, New Delhi, INDIA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002040063	A1	20020404	
	US 6559187	B2	20030506	
APPLICATION INFO.:	US 2001-923491	A1	20010807	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-223391P	20000807 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: RANBAXY PHARMACEUTICALS INC., Suite 2100, 600 College Road East, Princeton, NJ, 08540
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
LINE COUNT: 1042
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to a liquid formulation of **metformin** or its pharmaceutically acceptable salts thereof. The liquid pharmaceutical composition comprises a therapeutically effective amount of **metformin** or its pharmaceutically acceptable salt, in a liquid carrier, which may also include a sweetener that does not increase the blood glucose level of a subject after ingestion thereof. In one embodiment, it may also include alkyl hydroxyethylcellulose, and/or a polyhydroxy alcohol. In another embodiment, the carrier may contain a sweetener, mineral acid, and bicarbonate salt maintained at a pH of 4.0 to 9.0. It is useful for treating hyperglycemia and diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 26 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:214468 USPATFULL
TITLE: Liquid formulation of **metformin**
INVENTOR(S): Chandran, Ravi, Bolton Landing, NY, UNITED STATES
Gogia, Ashish, New Delhi, INDIA

	NUMBER	KIND	DATE

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003149111	A1	20030807
APPLICATION INFO.:	US 2003-382442	A1	20030306 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-923491, filed on 7 Aug 2001, GRANTED, Pat. No. US 6559187

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-223391P	20000807 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JAYADEEP R. DESHMUKH, ESQ., RANBAXY PHARMACEUTICALS INC., Suite 2100, 600 College Road East, Princeton, NJ, 08540
NUMBER OF CLAIMS: 50
EXEMPLARY CLAIM: 1
LINE COUNT: 1044
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to a liquid formulation of **metformin** or its pharmaceutically acceptable salts thereof. The liquid pharmaceutical composition comprises a therapeutically effective amount of **metformin** or its pharmaceutically acceptable salt, in a liquid carrier, which may also include a sweetener that does not increase the blood glucose level of a subject after ingestion thereof. In one embodiment, it may also include alkyl hydroxyethylcellulose, and/or a polyhydroxy alcohol. In another embodiment, the carrier may contain a sweetener, mineral acid, and bicarbonate salt maintained at a pH of 4.0 to 9.0. It is useful for treating hyperglycemia and diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 27 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2001:147493 USPATFULL
TITLE: Controlled release **tablet** having a unitary core
INVENTOR(S): Chen, Chih-Ming, Davie, FL, United States
Cheng, Xiu Xiu, Davie, FL, United States
Chou, Joseph, Coral Springs, FL, United States
Jan, Steve, Coral Springs, FL, United States
PATENT ASSIGNEE(S): Andrx Pharmaceuticals, Inc., Davie, FL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6284275	B1	20010904
APPLICATION INFO.:	US 2000-590807		20000609 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-143876, filed on 31 Aug 1998, now patented, Pat. No. US 6099862
DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Seidleck, Brian K.
LEGAL REPRESENTATIVE: Hedman & Costigan P.C.
NUMBER OF CLAIMS: 39
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 2 Drawing Figure(s); 2 Drawing Page(s)
LINE COUNT: 639
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A controlled release pharmaceutical **tablet** containing antihyperglycemic drug and a hypoglycemic drug that does not contain an expanding or gelling polymer layer and comprising a core containing the antihyperglycemic drug and the hypoglycemic drug, a semipermeable **coating** membrane surrounding the core and at least one passageway in the membrane to allow the drugs to be released from the

core.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 28 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:282377 HCAPLUS
DOCUMENT NUMBER: 138:292793
TITLE: Extended release pharmaceutical composition containing **metformin**
INVENTOR(S): Murpani, Deepak; Madan, Ashish; Arora, Vinod Kumar; Malik, Rajiv
PATENT ASSIGNEE(S): Ranbaxy Laboratories Limited, India
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003028704	A1	20030410	WO 2002-IB3997	20020927

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2001-DE1002 A 20010928
AB The present invention relates to an extended release pharmaceutical compn. contg. **metformin** and a rate controlling polymer and a process for its prepn. are described. The compn. has a water content of 3.2-10.0% by wt. and improved hardness and friability. For example, **tablets** with water content of 2.8% were prepd. by conventional dry granulation technique from a blend of **metformin** hydrochloride 500.0 mg, sodium CM-**cellulose** 36.0 mg, microcryst. **cellulose** 60.0 mg, hydroxypropyl Me **cellulose** 398.0 mg, magnesium stearate 6 mg, and water as needed. Hardness of the **tablets** obtained was 16.9 Kp and friability was 0.43% by wt. Release of **metformin** hydrochloride from **tablets** after 1h, 4 h, 8 h, and 12 h was 27.1%, 58.7%, 84.9%, and 97.8%, resp.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 29 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2001:25927 USPATFULL
TITLE: Method of reducing serum glucose levels
INVENTOR(S): Byrd, Edward A., San Francisco, CA, United States
Janjikhel, Rajiv, Owings Mills, MD, United States
PATENT ASSIGNEE(S): Medical Research Institute, San Bruno, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6191162	B1	20010220
APPLICATION INFO.:	US 1999-288253		19990408 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1998-112623, filed on 9 Jul 1998

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-102605P	19981001 (60)
	US 1998-87203P	19980528 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
ASSISTANT EXAMINER: Kim, Jennifer
LEGAL REPRESENTATIVE: Bozicevic, KarlBozicevic, Field, Francis LLP
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 1694
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A controlled release formulation of lipoic acid is administered to a patient resulting in reduced serum glucose levels. The formulation comprises a pharmaceutically acceptable carrier and is designed to prevent degradation of the lipoic acid in the gastrointestinal tract and to release the lipoic acid in a controlled manner thereby obtaining a desired lipoic acid serum level over an extended period resulting in reduced serum glucose levels over that period.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 30 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2001:144935 USPATFULL
TITLE: EXTENDING THE DURATION OF DRUG RELEASE WITHIN THE STOMACH DURING THE FED MODE
INVENTOR(S): SHELL, JOHN W., HILLSBOROUGH, CA, United States
LOUIE-HELM, JENNY, UNION CITY, CA, United States
MARKEY, MICHELINE, SANTA CRUZ, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001018070	A1	20010830
	US 6340475	B2	20020122
APPLICATION INFO.:	US 1999-282233	A1	19990329 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1997-870509, filed on 6 Jun 1997, ABANDONED A 371 of International Ser. No. WO 1998-US11302, filed on 5 Jun 1998, UNKNOWN
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: M HENRY HEINES, TOWNSEND TOWNSEND & CREW, TWO EMBARCADERO CENTER, 8TH FLOOR, SAN FRANCISCO, CA, 941113834
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 1530
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Drugs are formulated as unit oral dosage forms by incorporating them into polymeric matrices comprised of hydrophilic polymers that swell upon imbibition of water to a size that is large enough to promote retention of the dosage form in the stomach during the fed mode. The oral formulation is designed for gastric retention and controlled delivery of an incorporated drug into the gastric cavity, and thus administered, the drug is released from the matrix into the gastric fluid by solution diffusion. The swollen polymeric matrix, having achieved sufficient size, remains in the gastric cavity for several hours if administered while the patient is in the fed mode, and remains intact long enough for substantially all of the drug to be released before substantial dissolution of the matrix occurs. The swelling matrix lowers the accessibility of the gastric fluid to the drug and thereby reduces the drug release rate. This process, together with diffusion retardation by selection of specific polymers, polymer molecular

weights, and other variables, results in a sustained and controlled delivery rate of the drug to the gastric cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 31 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2002:98925 USPATFULL
TITLE: Extending the duration of drug release within the stomach during the fed mode
INVENTOR(S): Shell, John W., Hillsborough, CA, UNITED STATES
Louie-Helm, Jenny, Union City, CA, UNITED STATES
Markey, Micheline, Santa Cruz, CA, UNITED STATES
PATENT ASSIGNEE(S): DepoMed, Inc., Menlo Park, CA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002051820	A1	20020502
APPLICATION INFO.:	US 2001-990061	A1	20011120 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-282233, filed on 29 Mar 1999, PENDING Continuation-in-part of Ser. No. US 1997-870509, filed on 6 Jun 1997, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 1493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Drugs are formulated as unit oral dosage forms by incorporating them into polymeric matrices comprised of hydrophilic polymers that swell upon imbibition of water to a size that is large enough to promote retention of the dosage form in the stomach during the fed mode. The oral formulation is designed for gastric retention and controlled delivery of an incorporated drug into the gastric cavity, and thus administered, the drug is released from the matrix into the gastric fluid by solution diffusion. The swollen polymeric matrix, having achieved sufficient size, remains in the gastric cavity for several hours if administered while the patient is in the fed mode, and remains intact long enough for substantially all of the drug to be released before substantial dissolution of the matrix occurs. The swelling matrix lowers the accessibility of the gastric fluid to the drug and thereby reduces the drug release rate. This process, together with diffusion retardation by selection of specific polymers, polymer molecular weights, and other variables, results in a sustained and controlled delivery rate of the drug to the gastric cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 32 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:57124 USPATFULL
TITLE: Extending the duration of drug release within the stomach during the fed mode
INVENTOR(S): Shell, John W., Hillsborough, CA, UNITED STATES
Louie-Helm, Jenny, Union City, CA, UNITED STATES
Markey, Micheline, Santa Cruz, CA, UNITED STATES
PATENT ASSIGNEE(S): DepoMed, Inc., Menlo Park, CA, 94025 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003039688	A1	20030227
APPLICATION INFO.:	US 2001-45823	A1	20011106 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-282233, filed on 29 Mar 1999, GRANTED, Pat. No. US 6340475
Continuation-in-part of Ser. No. US 1997-870509, filed on 6 Jun 1997, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 1439
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Drugs are formulated as unit oral dosage forms by incorporating them into polymeric matrices comprised of hydrophilic polymers that swell upon imbibition of water to a size that is large enough to promote retention of the dosage form in the stomach during the fed mode. The oral formulation is designed for gastric retention and controlled delivery of an incorporated drug into the gastric cavity, and thus administered, the drug is released from the matrix into the gastric fluid by solution diffusion. The swollen polymeric matrix, having achieved sufficient size, remains in the gastric cavity for several hours if administered while the patient is in the fed mode, and remains intact long enough for substantially all of the drug to be released before substantial dissolution of the matrix occurs. The swelling matrix lowers the accessibility of the gastric fluid to the drug and thereby reduces the drug release rate. This process, together with diffusion retardation by selection of specific polymers, polymer molecular weights, and other variables, results in a sustained and controlled delivery rate of the drug to the gastric cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 33 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:133545 USPATFULL
TITLE: Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
INVENTOR(S): Louie-Helm, Jenny, Union City, CA, UNITED STATES
Berner, Bret, El Granada, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003091630	A1	20030515
APPLICATION INFO.:	US 2001-14750	A1	20011025 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: REED & EBERLE LLP, 800 MENLO AVENUE, SUITE 210, MENLO PARK, CA, 94025
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 5 Drawing Page(s)
LINE COUNT: 1906
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Erodible, gastric-retentive dosage forms are provided that are formulated using the in vitro drug release profile obtained with USP Disintegration test equipment rather the USP Dissolution Apparatus. The invention is premised on the discovery that the USP Disintegration Test and modified versions thereof are far more predictive of the in vivo release profile for a controlled release dosage form than is the standard USP Dissolution Test, particularly controlled release dosage forms of the swellable, erodible type. The dosage forms generally comprise particles of a biocompatible, hydrophilic polymer having the active agent incorporated therein, wherein the particles are optionally but preferably compacted into a **tablet** or loaded into a

capsule. The dosage forms can be used to deliver water-insoluble or sparingly soluble drugs as well as water-soluble drugs, providing that the latter are coated with a protective **coating** or contained in a protective vesicle.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 34 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1997:128753 HCAPLUS
DOCUMENT NUMBER: 126:229547
TITLE: Use of **cellulose** ether containing excipients with microcrystalline **cellulose** for the production of pellets containing **metformin** hydrochloride by the process of extrusion-spheronization
AUTHOR(S): Gouldson, M. P.; Deasy, P. B.
CORPORATE SOURCE: Dep. Pharmaceutics, Trinity Coll. Univ. Dublin, Dublin, 4, Ire.
SOURCE: Journal of Microencapsulation (1997), 14(2), 137-153
CODEN: JOMIEF; ISSN: 0265-2048
PUBLISHER: Taylor & Francis
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The project is concerned mainly with the evaluation of 2 **cellulose** ether contg. excipients, Aquacoat WG and Avicel 955 MCC for the improved extrusion-spheronization of **metformin**-HCl. Factorially designed expts. subject to statistical analyses were employed and products obtained were evaluated by sieve, packing d. and image anal., SEM and dissoln. testing at pH 6.cntdot.8. Aquacoat WG did not improve the ease of spheronization of drug mixes contg. microcryst. **cellulose** wetted with the optimum level of water. However, Avicel 955 MCC, a new exptl. excipient contg. 95% microcryst. **cellulose** and 5% Me **cellulose**, did aid ease of spheronization facilitating acceptable yield of good spheres with high drug loadings (70%). Avicel 955 MCC-contg. drug mixes were more tolerant to minor alterations in level of hydration and yielded spheres which showed a small retardation of drug release despite the very high soly. of **metformin**-HCl.

L19 ANSWER 35 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2001:178655 USPATFULL
TITLE: Solid oral dosage form comprising a combination of **metformin** and glibenclamide
INVENTOR(S): Bonhomme, Yves, Charbonnieres les Bains, France
Nicholson, Geoffrey, Aylesbury, United Kingdom
Cave, Gillian, Ellesmere Port, United Kingdom
Nicholson, Sarah J., Helsby, United Kingdom
PATENT ASSIGNEE(S): LIPHA, Lyons, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6303146	B1	20011016
APPLICATION INFO.:	US 1999-353141		19990714 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1998-401781	19980715

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Page, Thurman K.
ASSISTANT EXAMINER: Tran, S.
LEGAL REPRESENTATIVE: Oblon, Spivak, McClelland, Maier & Neustadt, P.C.
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Figure(s); 3 Drawing Page(s)

LINE COUNT: 418
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention relates to a solid oral dosage form comprising a combination of **metformin** and glibenclamide in which the size of glibenclamide is such that the glibenclamide bioavailability is comparable to the glibenclamide bioavailability obtained with a separate administration of **metformin** and glibenclamide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 36 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:150455 HCAPLUS
DOCUMENT NUMBER: 138:175909
TITLE: Directly compressible extended-release matrix formulation for **metformin** hydrochloride
INVENTOR(S): Kumar, Vijai; McGuffy, Kevin Scott
PATENT ASSIGNEE(S): USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6524618	B1	20030225	US 2001-879748	20010612

PRIORITY APPLN. INFO.: US 2001-879748 20010612
AB An extended-release matrix formulation capable of being directly compressed into **tablets** comprises **metformin**-HCl blended with specific excipients. The excipients used in the formulation enhance the flow and compaction properties of the drug and insure that the formulation is directly compressible into a **tablet** contg. 100-800 mg, preferably 250-750 mg, of **metformin**-HCl in unit dosage form. Each **tablet** produced by direct compression of the formulation has the desired hardness and dissoln. characteristics such that the drug is released in the body of the subject over an extended period of time. **Tablets** were prepd. from **metformin** -HCl 750.00, lactose 161.55, hydroxypropyl **cellulose** 463.50, hydroxyethyl **cellulose** 154.50, colloidal silicon dioxide 7.73, and Mg stearate 7.72 mg.
REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 37 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:899701 HCAPLUS
DOCUMENT NUMBER: 136:74508
TITLE: In vitro comparative study of biopharmaceutical properties of **metformin** hydrochloride **tablets** marketed in Brazil
AUTHOR(S): Gomes de Pinho, Jose de Jesus Ribeiro; Storpirtis, Silvia
CORPORATE SOURCE: Fac. Farmacia Bioquimica, Univ. Federal Juiz de Fora, Brazil
SOURCE: Revista Brasileira de Ciencias Farmaceuticas (2001), 37(1), 95-105
CODEN: RBCFFM; ISSN: 1516-9332
PUBLISHER: Universidade de Sao Paulo, Faculdade de Ciencias Farmaceuticas
DOCUMENT TYPE: Journal
LANGUAGE: Portuguese
AB In the present work **metformin** hydrocloride 850 mg **tablets**, from two different labs. A and B (three batches of each lab.), were evaluated using phys. and physicochem. expts. according to

British Pharmacopea (1993). The drug was assayed using UV spectrophotometry at 233 nm. The results showed that two batches from lab. B were not according to the specification because they presented irregular hardness 2.57 .+-. 0.98 and 2.89 .+-. 0.62 kgf, under minimal values of Farmacopeia Brasileira 4. ed. (Parte I), which is 3 kgf. All the batches from lab. A, which had film **coating**, showed irregular hardness (22.99 .+-. 1.49, 8.64 .+-. 0.99 and 19.02 .+-. 2.36). The products A and B developed different dissoln. profiles, resulting in order 1 kinetic. The dissoln. rate from the product A was the lowest, presenting dissoln. rate const. (Kd = 0.0518 min-1), dissoln. half-life (Td50 = 6.93 min), dissoln. efficiency (DE = 74,75%) and correlation coeff. (r = 0.9885), while the product B showed Kd = 0.0703; Td50 = 4.47 min; DE = 80,46% and r = 0.9986. Thermoanalitical tests TG/DTG and DSC demonstrated that the products suffered thermal decompn. in different temps., which can be attributed to the excipients which are distinct in the formulations.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 38 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2001:176241 USPATFULL
TITLE: Controlled release lipoic acid
INVENTOR(S): Byrd, Edward A., San Francisco, CA, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001028896	A1	20011011
	US 6572888	B2	20030603
APPLICATION INFO.:	US 2001-755890	A1	20010105 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-288245, filed on 8 Apr 1999, GRANTED, Pat. No. US 6197340
Continuation-in-part of Ser. No. US 1998-112623, filed on 9 Jul 1998, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-102605P	19981001 (60)
	US 1998-87203P	19980528 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Karl Bozicevic, BOZICEVIC, FIELD & FRANCIS LLP, 200 Middlefield Road, Suite 200, Menlo Park, CA, 94025
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1438
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials provide for gradual release of the lipoic acid in a manner which makes it possible to substantially increase the period of time over which therapeutic levels of lipoic acid are maintained relative to a quick release formulation. These features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired therapeutic results.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 39 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:84280 HCAPLUS
DOCUMENT NUMBER: 132:127735
TITLE: **Tablets** for extended release of a drug in the stomach
INVENTOR(S): Bonhomme, Yves; Nicholson, Geoffroy

PATENT ASSIGNEE(S): LIPHA, Lyonnaise Industrielle Pharmaceutique, Fr.
SOURCE: Eur. Pat. Appl., 8 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 976395	A1	20000202	EP 1998-401956	19980730
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AU 9957318	A1	20000221	AU 1999-57318	19990728
WO 2000006129	A1	20000210	WO 1999-EP5746	19990729
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: EP 1998-401956 A 19980730
WO 1999-EP5746 W 19990729

AB The invention relates to a **tablet** for extended release of a drug in the stomach, comprising granules of the drug in a hydrophilic matrix, the granules being coated with a **coating** comprising a source of a carbon dioxide and the **coating** granules being blended with an agent inducing the release of carbon dioxide and tabletting aids. Granules were formulated contg. **metformin**.cntdot.HCl 62.42, Methocel K100M 15.9, and PVP K30 4.6 % and the granules were sprayed with PVP K30 1.6 and NaHCO3 12 % and mixed with citric acid 2.1 and Mg stearate 1.22 % for compression to give a **tablet** contg. **metformin** .cntdot.HCl 500 mg/each.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 40 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:29898 USPATFULL
TITLE: Pharmaceutical composition
INVENTOR(S): Matharu, Amol Singh, Cranbury, NJ, UNITED STATES
Patel, Mahendra R., East Brunswick, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003021841	A1	20030130	
APPLICATION INFO.:	US 2002-183881	A1	20020627	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302613P	20010702 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS CORPORATION, PATENT AND TRADEMARK DEPT, 564 MORRIS AVENUE, SUMMIT, NJ, 079011027
NUMBER OF CLAIMS: 29
EXEMPLARY CLAIM: 1
LINE COUNT: 565
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a process for preparing **tablet** dosage forms of poorly-compressible pharmaceutical agents and to

tablet dosage forms prepared according to the inventive process. The inventive process is especially useful for preparing **tablets** of the poorly-compressible drug **metformin** HCl.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 41 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:152383 USPATFULL
TITLE: **Metformin** Hydrochloride **tablets**
INVENTOR(S): Sherman, Bernard Charles, Willowdale, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003104049	A1	20030605
APPLICATION INFO.:	US 2001-2130	A1	20011205 (10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: NIXON & VANDERHYE P.C., 8th Floor, 1100 North Glebe Road, Arlington, VA, 22201-4714
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 209
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Tablets** for oral administration comprising **metformin** hydrochloride and methylcellulose.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 42 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1996:226313 HCAPLUS
DOCUMENT NUMBER: 124:270593
TITLE: **Metformin** controlled-release formulations
INVENTOR(S): Moeckel, Joern; Gabel, Rolf-Dieter; Woog, Heinrich
PATENT ASSIGNEE(S): boehringer Mannheim Gmbh, Germany
SOURCE: Ger. Offen., 13 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4432757	A1	19960321	DE 1994-4432757	19940914
ZA 9507670	A	19970313	ZA 1995-7670	19950913
WO 9608243	A1	19960321	WO 1995-EP3610	19950914
W: AU, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KR, KZ, LT, LV, MX, NO, NZ, PL, RO, RU, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9535672	A1	19960329	AU 1995-35672	19950914
EP 781129	A1	19970702	EP 1995-932741	19950914
EP 781129	B1	20030702		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10505604	T2	19980602	JP 1995-509915	19950914
IL 115309	A1	20000831	IL 1995-115309	19950914
AT 244004	E	20030715	AT 1995-932741	19950914
US 5955106	A	19990921	US 1997-793753	19970314

PRIORITY APPLN. INFO.: DE 1994-4432757 A 19940914
WO 1995-EP3610 W 19950914

AB **Metformin** is formulated with a hydrocolloid-forming substance (e.g. a gum, **cellulose** deriv., or synthetic polymer) as release-controlling agent with a residual moisture content of 0.5-3 wt.%. These formulations can be compressed into **tablets** or pellets without use of org. solvents, and can be prepd. with a high

metformin content. Thus, **tablet** cores were prepd. each contg. **metformin**-HCl 850.00, hydroxypropylmethylcellulose 60.00, PVP 38.00, and Mg stearate 5.00 mg, and coated with a mixt. of hydroxypropylmethylcellulose 20.00, ethylcellulose 12.00, Macrogol 4.00, and TiO2 4.00 mg.

L19 ANSWER 43 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2002:130005 USPATFULL
TITLE: Composition containing ascorbic acid
INVENTOR(S): Noguchi, Hiroshi, Kawanishi, JAPAN
Taiji, Mutsuo, Takatsuki, JAPAN
Yamaga, Hiroshi, Suita, JAPAN
Itakura, Yasushi, Nara, JAPAN
Ichihara, Junji, Takatsuki, JAPAN
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Co., Ltd., Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6399658	B1	20020604	
	WO 9827982		19980702	
APPLICATION INFO.:	US 1999-319573		19990609	(9)
	WO 1997-JP4662		19971217	
			19990609	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-356302	19961224

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Krass, Frederick
ASSISTANT EXAMINER: Jagoe, Donna
LEGAL REPRESENTATIVE: Birch, Stewart, Kolasch & Birch, LLP
NUMBER OF CLAIMS: 6
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 787
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB L-ascorbic acid, L-ascorbic acid derivatives and salts thereof can reduce lactic acid levels in blood, and are useful for treating lactic acidosis and the like caused by administration of amoxapine, theophylline, **metformin**, phenformin, buformin, nalidixic acid, hopantenic acid, azidothymidine, dideoxycytidine, high caloric transfusion, propylene glycol, ethylene glycol, xylitol, lactose, sorbitol or the like.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 44 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:353262 HCAPLUS
DOCUMENT NUMBER: 136:345841
TITLE: Controlled release **metformin** compositions
INVENTOR(S): Chen, Chih-Ming; Cheng, Xiu-Xiu; Jan, Steve; Chou, Joseph
PATENT ASSIGNEE(S): Andrx Corporation, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002036100 A1 20020510 WO 2001-US48306 20011030
WO 2002036100 C2 20030724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2002030830 A5 20020515 AU 2002-30830 20011030
EP 1335708 A1 20030820 EP 2001-991078 20011030
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.: US 2000-705625 A 20001103
US 2000-705630 A 20001103
WO 2001-US48306 W 20011030

AB A compn. and methods thereof for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form contg. preferably a biguanide drug such as **metformin**, on a once-a-day basis. The dosage form provides a mean time to max. plasma concn. (Tmax) of the drug which occurs at 5.5 to 7.5 h after oral administration on a one-a-day basis to human patients. Preferably, the dose of drug is administered at dinner time to a patient in the fed state. A **tablet** core was formulated contg. **metformin**.cntdot.HCl 500, Povidone 36, Na lauryl sulfate 25.8, and Mg stearate 2.8 mg/**tablet** was coated to have a sustained-release **coating** contg. **cellulose** acetate 21.5, triacetin 1.3, and PEG-400 2.5 mg/**tablet**. The coated **tablets** were laser drilled two holes.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 45 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:881038 HCAPLUS
DOCUMENT NUMBER: 139:57791
TITLE: Preparation and in vitro release of intragastric floating system of **metformin** hydrochloride
AUTHOR(S): Huang, Dong-po; Wang, Yuan; Jiang, Guo-qiang; Chen, Jun; Ding, Fu-xin
CORPORATE SOURCE: Department of Chemical Engineering, Tsinghua University, Beijing, 100084, Peop. Rep. China
SOURCE: Jingxi Huagong (2002), 19(10), 609-611
CODEN: JIHUFJ; ISSN: 1003-5214
PUBLISHER: Jingxi Huagong Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese

AB Intragastric floating sustained release **tablets** of **metformin** hydrochloride were prepd. utilizing the technique of wet granulation followed by compression into **tablets**. The **tablets** possessed superior floating property and could hold consistent drug release rate within over 8 h. The floating lag time decreased with increase in the hydroxypropyl Me **cellulose** content in the **tablet**. The relation between the **tablet** d. and the mass fraction of octadecyl alc. can be correlated. The in vitro release results indicated that the drug release was attributed to dual function of diffusion and matrix dissoln. and the kinetics was found to follow the Higuchi equation.

L19 ANSWER 46 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:417505 HCAPLUS
DOCUMENT NUMBER: 139:12256
TITLE: Pharmaceutical composition containing

metformin and a 4-oxobutanoic acid for the treatment of diabetes
INVENTOR(S): Moinet, Gerard; Marais, Dominique
PATENT ASSIGNEE(S): Lipha, Fr.
SOURCE: Fr. Demande, 21 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2832633	A1	20030530	FR 2001-15398	20011128
WO 2003045368	A1	20030605	WO 2002-EP12355	20021106

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: FR 2001-15398 A 20011128
OTHER SOURCE(S): MARPAT 139:12256
AB Pharmaceutical compn. comprise **metformin** or its pharmaceutically acceptable salts and acids and a 4-oxo-butanoic acid deriv., in combination with one or more excipients. The compns. are particularly useful for the treatment of the noninsulino-dependent diabetes. A **tablet** contained **metformin** 7.7, microcryst. **cellulose** 76.7, lactose powder 4.6, hydroxy pr **cellulose** 1.8, sodium **croscarmellose** 1.8, colloidal silica (Aerosil) 0.3, and magnesium stearate 0.9%.
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 47 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2002:239028 USPATFULL
TITLE: Inhibition of emetic effect of **metformin** with 5-HT3 receptor antagonists
INVENTOR(S): Cowles, Verne E., Dublin, CA, United States
PATENT ASSIGNEE(S): DepoMed, Inc., Menlo Park, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6451808	B1	20020917
APPLICATION INFO.:	US 2000-691398		20001017 (9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Pryor, Alton Nathaniel
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew, LLP
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 444
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB **Metformin** is formulated as a pharmaceutical composition that also includes a 5-hydroxytryptamine-3 receptor antagonist to suppress the gastrointestinal side effects that are associated with **metformin** administration in many patients.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 48 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:434338 HCAPLUS
DOCUMENT NUMBER: 139:12295
TITLE: Pharmaceutical compositions comprising **metformin** and glibenclamide for the treatment of type-II diabetes mellitus
INVENTOR(S): Tosetti, Alessandro; Guiducci, Mauro; Viti, Giovanni
PATENT ASSIGNEE(S): Menarini International Operations Luxembourg S.A., Luxembourg
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003045355	A1	20030605	WO 2002-EP13497	20021129

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IT 2001-FI230 A 20011129
AB Orally administrable pharmaceutical compns. in the form of **tablets**, comprising glibenclamide and **metformin**, or pharmaceutically acceptable salts thereof, as active ingredients, maintained sep. from one another within the same compn., are described for the treatment of type-II diabetes mellitus.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 49 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:547376 HCAPLUS
DOCUMENT NUMBER: 133:155439
TITLE: Controlled release **tablets** containing biguanide and sulfonylurea
INVENTOR(S): Chen, Chih-ming; Cheng, Xiu Xiu; Chou, Joseph; Jan, Steve
PATENT ASSIGNEE(S): Andrx Corporation, USA
SOURCE: U.S., 9 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6099862	A	20000808	US 1998-143876	19980831
CA 2341908	AA	20000309	CA 1999-2341908	19990831
JP 2003520759	T2	20030708	JP 2000-567214	19990831
US 6284275	B1	20010904	US 2000-590807	20000609

PRIORITY APPLN. INFO.: US 1998-143876 A 19980831

WO 1999-US19978 W 19990831

AB A controlled release **tablet** contg. antihyperglycemic drug (that decreases hepatic glucose prodn.) and a hypoglycemic drug (that stimulates the release of insulin from the pancreas), that does not contain an expanding or gelling polymer layer, comprises a core of both the drugs, a semipermeable **coating** membrane surrounding the core and at least one passageway in the membrane to allow the drugs to be released from the core. A controlled release **tablet** contg. 500 mg **metformin**-HCl and 5 mg glipizide and having the following formulation was prepd.: **metformin**-HCl 87.77, glipizide 0.88, Povidone 6.31, sodium lauryl sulfate 4.54, and Mg stearate 0.50%. The granules contg. the above formulation were compressed into **tablets** and coated with **cellulose** acetate 85, triacetin 5, and PEG 10%.

REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 50 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:334961 HCAPLUS
DOCUMENT NUMBER: 138:343914
TITLE: Optimal polymer mixtures for gastric retentive **tablets**
INVENTOR(S): Gusler, Gloria; Berner, Bret; Chau, Mei; Padua, Aimee
PATENT ASSIGNEE(S): Depomed, Inc., USA
SOURCE: PCT Int. Appl., 22 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035177	A2	20030501	WO 2002-US33968	20021022
WO 2003035177	A3	20030814		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003104053	A1	20030605	US 2001-29134	20011025

PRIORITY APPLN. INFO.: US 2001-29134 A 20011025

AB Unit dosage form **tablets** for the delivery of pharmaceuticals are formed of the pharmaceutical dispersed in a solid unitary matrix that is formed of a combination of PEG and hydroxypropyl Me **cellulose**. The combination offers unique benefits in terms of release rate control and reproducibility while allowing both swelling of the **tablet** to effect gastric retention and gradual disintegration of the **tablet** to clear the **tablet** from the gastrointestinal tract after release of the drug has occurred. Thus, **tablets** contained gabapentin 60.0,,PEG 24.3, HPMC 14.7, and Mg stearate 1.0%.

=>

L19 ANSWER 51 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:42092 HCAPLUS
DOCUMENT NUMBER: 138:112443
TITLE: **Tablet** compositions for poorly-compressible pharmaceuticals
INVENTOR(S): Matharu, Amol Singh; Patel, Mahendra R.
PATENT ASSIGNEE(S): Geneva Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 20 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003004009	A1	20030116	WO 2002-US20323	20020627

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003021841	A1	20030130	US 2002-183881	20020627

PRIORITY APPLN. INFO.: US 2001-302613P P 20010702
AB The present invention relates to a process for prepg. **tablet** dosage forms of poorly-compressible pharmaceuticals and to **tablet** dosage forms. The process is esp. useful for prepg. **tablets** of the poorly-compressible drug **metformin**-HCl. Thus, **tablets** contained **metformin**-HCl 500, HPMC 320, stearyl alc. 200, and Mg stearate mg/unit.
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 52 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:613651 HCAPLUS
DOCUMENT NUMBER: 131:233581
TITLE: Biphasic controlled-release delivery system for high solubility pharmaceuticals
INVENTOR(S): Timmins, Peter; Dennis, Andrew B.; Vyas, Kiren A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9947128	A1	19990923	WO 1999-US5233	19990310

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2320900	AA	19990923	CA 1999-2320900	19990310

AU 9931828	A1	19991011	AU 1999-31828	19990310	
AU 736951	B2	20010809			
EP 1063973	A1	20010103	EP 1999-913842	19990310	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI					
BR 9908911	A	20011002	BR 1999-8911	19990310	
JP 2002506812	T2	20020305	JP 2000-536368	19990310	
PRIORITY APPLN. INFO.:			US 1998-44446	A 19980319	
			WO 1999-US5233	W 19990310	

AB A biphasic controlled-release delivery system for pharmaceuticals which have high water soly., such as the antidiabetic **metformin**-HCl, is provided which provides a dosage form that has prolonged gastric residence and includes (1) an inner solid particulate phase formed of substantially uniform granules contg. a pharmaceutical having a high water soly. and .gtoreq.1 hydrophilic polymer, .gtoreq.1 hydrophobic polymer, and/or .gtoreq.1 hydrophobic material such as waxes, fatty alcs., and/or fatty acid esters, and (2) an outer solid continuous phase in which the granules of the inner solid particulate phase are embedded and dispersed. The outer solid continuous phase includes .gtoreq.1 hydrophilic polymer, .gtoreq.1 hydrophobic polymer, and/or .gtoreq.1 hydrophobic material such as waxes, fatty alcs., and/or fatty acid esters, which may be compressed into **tablets** or filled into **capsules**. Methods for forming the biphasic controlled release delivery system and using it for treating diabetes are also provided. Thus, 500 g **metformin**-HCl was granulated with a dispersion of 25 g ethylcellulose in 100 mL 95% EtOH, dried, sieved, blended with hydroxypropylmethylcellulose 2208 USP 351.5, hydroxypropylmethylcellulose 2910 USP 10, microcryst. **cellulose** 100.5 g, and 1% Mg stearate, and compressed into biphasic **tablets** each contg. 500 mg **metformin**-HCl. The percentage of **metformin**-HCl released from these **tablets** during in vitro testing was 38.1% after 1 h and 79.7% after 4 h.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 53 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:122783 HCAPLUS
DOCUMENT NUMBER: 136:172785
TITLE: Pharmaceutical composition comprising **metformin** and a 5-phenoxyalkyl-2,4-thiazolidinedione-type derivative
INVENTOR(S): Moinet, Gerard; Botton, Gerard; Mesangeau, Didier
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 18 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011721	A1	20020214	WO 2001-EP8512	20010724
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2812547	A1	20020208	FR 2000-10362	20000804
FR 2812547	B1	20021031		

AU 2001082010 A5 20020218 AU 2001-82010 20010724
EP 1305025 A1 20030502 EP 2001-960539 20010724
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
BR 2001012915 A 20030708 BR 2001-12915 20010724
NO 2003000518 A 20030203 NO 2003-518 20030203
PRIORITY APPLN. INFO.: FR 2000-10362 A 20000804
WO 2001-EP8512 W 20010724
OTHER SOURCE(S): MARPAT 136:172785
AB The present invention relates to an oral pharmaceutical compn. comprising, as active ingredients, **metformin**, optionally in the form of one of its pharmaceutically acceptable salts, and a 5-phenoxyalkyl-2,4-thiazolidinedione-type deriv. (I) for treatment of non-insulin-dependent diabetes. The wt. ratio of **metformin** or its salt to the compd. I, e.g., 5-[2-(4-cyanophenoxy)ethyl]thiazolidine-2,4-dione (CRE 16336), varies from 1:1 to 40:1. For example, a **tablet** was prepd. contg. **metformin** 850 mg, CRE 16336 50 mg, lactose 99 mg, hydroxypropyl **cellulose** 35 mg, sodium **croscarmellose** 55 mg, and magnesium stearate 11 mg. The **metformin** and CRE 16336 combination brings about normalization of the glycemia at doses where, given sep., these two products are without effect on the hyperglycemia.
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 54 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:338335 HCAPLUS
DOCUMENT NUMBER: 134:344604
TITLE: Antidiabetic formulation containing **metformin** and sulfonylurea
INVENTOR(S): Piper, Beth Anne
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 76 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032158	A2	20010510	WO 2000-US28467	20001013
WO 2001032158	A3	20020829		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002177602	A1	20021128	US 1999-432465	19991103
US 6586438	B2	20030701		
EP 1253944	A2	20021106	EP 2000-970913	20001013
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000015295	A	20030624	BR 2000-15295	20001013
NO 2002002086	A	20020624	NO 2002-2086	20020502
BG 106732	A	20030228	BG 2002-106732	20020522
LT 5025	B	20030625	LT 2002-62	20020524

PRIORITY APPLN. INFO.: US 1999-432465 A 19991103
WO 2000-US28467 W 20001013
AB A low dose antidiabetic formulation adapted for treating e.g., Type II

diabetes contains a combination of **metformin** (at <800 mg/day) and at least 1 other antidiabetic agent such as a sulfonylurea. This combination provides at least about substantially equiv. efficacy in treating diabetes as do antidiabetic formulations contg. **metformin** employed in dosages prescribed in generally accepted medical practice for first line therapy in treating diabetes, but with substantially reduced side effects, such as hypoglycemia and/or gastrointestinal distress. A method for treating diabetes in drug naive human patients is also provided employing the above formulation to reduce insulin resistance and/or post-prandial glucose excursion and/or Hb 1Ac, and/or increase post-prandial insulin, thereby treating the diabetes. Thus, **tablets** contained **metformin**-HCl 250.0, glyburide 1.25, **croscarmellose** sodium 7.00, Povidone 10.00, microcryst. **cellulose** 28.25, Mg stearate 2.25, and HPMC film-**coating** 6 mg. The effectiveness of this combination drug in producing hypoglycemia was demonstrated clin.

L19 ANSWER 55 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:845479 HCAPLUS
DOCUMENT NUMBER: 137:342124
TITLE: Biphasic controlled-release delivery systems for high solubility pharmaceuticals
INVENTOR(S): Timmins, Peter; Dennis, Andrew B.; Vyas, Kiren A.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S., 16 pp., Cont.-in-part of U.S. Ser. No. 44,446, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6475521	B1	20021105	US 1999-398107	19990916

PRIORITY APPLN. INFO.: US 1998-44446 B2 19980319

AB A biphasic controlled release delivery system for pharmaceuticals which have high water soly., such as the antidiabetic, **metformin**-HCl, provides a dosage form that has prolonged gastric residence so that a dosing regimen of at least one gram **metformin**, once daily, may be achieved while providing effective control of plasma glucose. The delivery system includes (1) an inner solid particulate phase formed of substantially uniform granules contg. a pharmaceutical having a high water soly., and 1 or more hydrophilic polymers, 1 or more hydrophobic polymers and/or one or more hydrophobic materials such as 1 or more waxes, fatty alcs. and/or fatty acid esters, and (2) an outer solid continuous phase in which the above granules of inner solid particulate phase are embedded and dispersed throughout, the outer solid continuous phase including hydrophilic polymers, hydrophobic polymers and/or hydrophobic materials such as waxes, fatty alcs. and/or fatty acid esters, which may be compressed into **tablets** or filled into **capsules**. Methods for forming the so-described biphasic controlled release delivery system and using such biphasic controlled release delivery system for treating diabetes are also provided. Et **cellulose** N10 NF (25 g) was dissolved/dispersed in 100 mL ETOH. This dispersion was gradually added to 500 g **metformin**-HCl in a planetary mixer to produce a uniform damp granulation. The granulation was dried at 55.degree. for 1 h and passed through a 0.8-mm aperture screen to break down agglomerates. The **metformin**-Et **cellulose** granules (541 g) were blended with 351.5 g hydroxypropyl Me **cellulose** 2208 USP (100,000 cps grade), 10 g hydroxypropyl Me **cellulose** 2910 USP, and 100.5 g microcryst. **cellulose** in a planetary mixer for 10 min. Finally this mix was lubricated with 1% MG stearate and compressed into **capsule**-shaped **tablets**, each contg. 500 mg

metformin-HCl.
REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 56 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:152387 USPATFULL
TITLE: OPTIMAL POLYMER MIXTURES FOR GASTRIC RETENTIVE **TABLETS**
INVENTOR(S): Gusler, Gloria, Cupertino, CA, UNITED STATES
Berner, Bret, El Granada, CA, UNITED STATES
Chau, Mei, Sunnyvale, CA, UNITED STATES
Padua, Aimee, Daly City, CA, UNITED STATES
PATENT ASSIGNEE(S): DepoMed, Inc., Menlo Park, CA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003104053	A1	20030605	
APPLICATION INFO.:	US 2001-29134	A1	20011025	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Unit dosage form **tablets** for the delivery of pharmaceuticals are formed of the pharmaceutical dispersed in a solid unitary matrix that is formed of a combination of poly(ethylene oxide) and hydroxypropyl methylcellulose. The combination offers unique benefits in terms of release rate control and reproducibility while allowing both swelling of the **tablet** to effect gastric retention and gradual disintegration of the **tablet** to clear the **tablet** from the gastrointestinal tract after release of the drug has occurred.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 57 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2002:81525 USPATFULL
TITLE: Pharmaceutical composition comprising a combination of **metformin** and fibrate, and its use for the preparation of medicines intended to reduce hyperglycaemia
INVENTOR(S): Bonhomme, Yves, Charbonnieres les Bains, FRANCE
Briet, Philippe, Lyons, FRANCE
PATENT ASSIGNEE(S): Merck Patent Gesellschaft mit beschrankter Haftung, Darnstadt, GERMANY, FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6372790	B1	20020416	
	WO 9940904		19990819	
APPLICATION INFO.:	US 2000-601618		20001130	(9)
	WO 1999-EP614		19990130	
			20001130	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1998-1709	19980212

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Weddington, Kevin E.

LEGAL REPRESENTATIVE: Millen, White, Zelano & Branigan, P.C.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 363
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A pharmaceutical composition comprising: (i) **metformin**, optionally in the form one of its pharmaceutically acceptable salts; (ii) a fibrate selected from fenofibrate and bezafibrate; and optionally one or more pharmaceutically acceptable excipients, is suitable for use in the treatment of non-insulin-dependent diabetes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 58 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:122779 HCAPLUS
DOCUMENT NUMBER: 136:172783
TITLE: Liquid formulation of **metformin**
INVENTOR(S): Chandran, Ravi; Gogia, Ashish
PATENT ASSIGNEE(S): Ranbaxy Signature LLC, USA
SOURCE: PCT Int. Appl., 42 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002011716	A2	20020214	WO 2001-IB1409	20010807
WO 2002011716	A3	20020711		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001076598	A5	20020218	AU 2001-76598	20010807
US 2002040063	A1	20020404	US 2001-923491	20010807
US 6559187	B2	20030506		
BR 2001013102	A	20030708	BR 2001-13102	20010807
US 2003149111	A1	20030807	US 2003-382442	20030306

PRIORITY APPLN. INFO.:
US 2000-223391P P 20000807
US 2001-923491 A1 20010807
WO 2001-IB1409 W 20010807

AB An oral liq. compn. useful for treating hyperglycemia and diabetes comprises a therapeutically effective amt. of **metformin** or its pharmaceutically acceptable salt in a liq. carrier, i.e., water. The compn. further comprises a sweetener that does not increase the blood glucose level of a subject after ingestion, alkyl hydroxyethyl **cellulose**, a polyhydroxy alc., and a mineral acid and a bicarbonate salt to maintain a pH of 4.0-9.0. The compn. addnl. comprises an antihyperglycemic agent, e.g., glyburide or glipizide. For example, to 60 L of purified water, heated to 40.degree., a mixt. of 1.9 kg of polyethylene glycol and 142.5 g hydroxyethyl **cellulose** (Natrosol 250 HX) was added. Then **metformin**-HCl (19 kg), followed by 1.188 kg calcium saccharin, 114 g citric acid, 211.28 g potassium benzoate, and addnl. polyethylene glycol (9.5 kg) were slowly added to the mixt., while maintaining the temp. of 40.degree.. A 70% soln. of sorbitol (in water) (76 kg) was pumped slowly to the tank maintained at 40.degree., and addnl. polyethylene glycol (21.85 kg) and cherry flavor (190 g) were

added to the tank and mixed. The contents of the tank were cooled to 30.degree., and addnl. water was added until the vol. was 190 L to obtain a **metformin**-HCl liq. formulation. The liq. formulation of the present invention contg. **metformin** or its pharmaceutically acceptable salt has several advantages over a solid formulation. Unlike the solid formulation, the liq. formulation can be administered to children and adults who have difficulty swallowing large size **tablets**. Thus, the liq. formulation facilitates patient compliance. Moreover, the liq. formulation showed to be safer and potentially exhibits less adverse effects than if the **metformin** or its salts were in a different formulation.

L19 ANSWER 59 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:152393 USPATFULL
TITLE: Controlled release **tablets** of **metformin**
INVENTOR(S): Chawla, Manish, Rohini, INDIA
Raghuvanshi, Rajeev S., New Delhi, INDIA
Rampal, Ashok, Amritsar, INDIA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003104059	A1	20030605
APPLICATION INFO.:	US 2002-289070	A1	20021106 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	IN 2001-11342001	20011106

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Ranbaxy Pharmaceuticals Inc., Suite 2100, 600 College Road East, Princeton, NJ, 08540
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 363
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Controlled-release **metformin** and processes for their preparation, using a combination of non-ionic and anionic hydrophilic polymers, wherein the total hydrophilic polymer concentration is at least about 16% by weight of the composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 60 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:106816 USPATFULL
TITLE: Combination of FBPase inhibitors and antidiabetic agents useful for the treatment of diabetes
INVENTOR(S): van Poelje, Paul D., La Jolla, CA, UNITED STATES
Erion, Mark D., Del Mar, CA, UNITED STATES
Fujiwara, Toshihiko, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073728	A1	20030417
APPLICATION INFO.:	US 2001-900364	A1	20010705 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-216531P	20000706 (60)
	US 2000-215126P	20000629 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BROBECK, PHLEGER & HARRISON LLP, 12390 EL CAMINO REAL, SAN DIEGO, CA, 92130

NUMBER OF CLAIMS: 114
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 12671
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A combination therapy of at least one FBPase inhibitor and at least one other antidiabetic agent is disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 61 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:928247 HCAPLUS
DOCUMENT NUMBER: 138:333
TITLE: Method for treating type 2 diabetes with low-dose combination of **metformin** and glyburide
INVENTOR(S): Piper, Beth Anne
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U. S. Ser. No. 432,465.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002183345	A1	20021205	US 1999-460920	19991214
US 2002177602	A1	20021128	US 1999-432465	19991103
US 6586438	B2	20030701		
WO 2001032157	A2	20010510	WO 2000-US28311	20001013
WO 2001032157	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1229918	A2	20020814	EP 2000-972122	20001013
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003519621	T2	20030624	JP 2001-534362	20001013
BR 2000015294	A	20030715	BR 2000-15294	20001013
NO 2002002087	A	20020624	NO 2002-2087	20020502
BG 106733	A	20030228	BG 2002-106733	20020522
LT 5025	B	20030625	LT 2002-62	20020524

PRIORITY APPLN. INFO.:
US 1999-432465 A2 19991103
US 1999-460920 A 19991214
WO 2000-US28311 W 20001013

AB A method is provided for first line treatment of type 2 diabetes employing a combination of **metformin** and glyburide. A method for treating diabetes in drug naive human patients is also provided employing the above formulation to reduce insulin resistance and/or post-prandial glucose excursion and/or Hb A1c, and/or increase post-prandial insulin, thereby treating the diabetes. Hydroxypropylmethylcellulose film-coated **tablets** of **metformin** HCl and glyburide were prepd. and tested in drug naive patients with type 2 diabetes mellitus who have had inadequate glycemic control with diet and exercise. A low dose **metformin**-glyburide (250 mg/1.25 mg) formulation achieved glycemic control at least essentially equiv. to a high dose **metformin** -glyburide (500 mg/2.5 mg) formulation but with reduced incidence of side

effects.

L19 ANSWER 62 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:613646 HCAPLUS
DOCUMENT NUMBER: 131:233580
TITLE: Controlled release oral **tablet** having a unitary core
INVENTOR(S): Cheng, Xiu Xiu; Chen, Chih-Ming; Jan, Steve; Chou, Joseph
PATENT ASSIGNEE(S): Andrx Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9947125	A1	19990923	WO 1999-US6024	19990319
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6099859	A	20000808	US 1998-45330	19980320
CA 2324493	AA	19990923	CA 1999-2324493	19990319
AU 9931019	A1	19991011	AU 1999-31019	19990319
AU 739226	B2	20011004		
EP 1063971	A1	20010103	EP 1999-912705	19990319
R: CH, DE, DK, ES, FR, GB, IT, LI, NL, SE				
JP 2002506810	T2	20020305	JP 2000-536365	19990319
US 2001024659	A1	20010927	US 2000-726193	20001129
US 2002064556	A1	20020530	US 2001-16556	20011101
US 6495162	B2	20021217		

PRIORITY APPLN. INFO.: US 1998-45330 A 19980320
WO 1999-US6024 W 19990319
US 2000-594637 A1 20000615

AB A controlled release antihyperglycemic **tablet** that does not contain an expanding polymer comprises a core contg. the antihyperglycemic drug, a semipermeable membrane **coating** the core and at least one passageway in the membrane. A core was prepd. contg. **metformin** -HCL 90.54, Povidone 4.38, Na3PO4 4.58, and Mg stearate 0.5% and a sustained release coting comprised **cellulose** acetate 85, triacetin 5, and PEG 400 10%.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 63 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:490987 HCAPLUS
DOCUMENT NUMBER: 139:57931
TITLE: Antidiabetic formulation containing **metformin** and glipizide
INVENTOR(S): Li, Danping; Phusanti, Lawan; Desai, Divyakant S.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051293	A2	20030626	WO 2002-US39140	20021209

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003139461	A1	20030724	US 2001-23533	20011217

PRIORITY APPLN. INFO.: US 2001-23533 A 20011217

AB An antidiabetic pharmaceutical formulation is provided, esp. adapted for treating Type II diabetes, which includes a combination of **metformin** and glipizide in a manner to control moisture in the formulation so that the glipizide does not hydrolyze, yet the **metformin** is compressible, if necessary. Excipients that are used in the formulations are microcryst. **cellulose**, Povidone, **Croscarmellose** sodium, Mg stearate, and HPMC.

L19 ANSWER 64 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:793392 HCAPLUS

DOCUMENT NUMBER: 137:299938

TITLE: Timed pulse release composition containing swellable core and polymeric coat

INVENTOR(S): Shanghvi, Dilip Shantilal; Dharmadhikari, Nitin Bhalachandra; Zala, Yashoraj Rupsinh; Khanna, Satish C.

PATENT ASSIGNEE(S): Sun Pharmaceutical Industries Limited, India

SOURCE: PCT Int. Appl., 21 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002080887	A2	20021017	WO 2002-IN107	20020409
WO 2002080887	A3	20021128		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

WO 2003030920	A1	20030417	WO 2002-IN203	20021008
WO 2003030920	C2	20030626		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: IN 2001-MU325 A 20010410
IN 2001-MU984 A 20011008
WO 2002-IN107 A 20020409

AB The present invention provides a timed pulse release compn. comprising: (a) a core compn. comprising a therapeutically active agent, a swelling agent, and optionally water sol. compd.(s) for inducing osmosis, and (b) a coat compn. comprising one or more film forming polymers. Upon imbibing fluid from the surrounding, the core swells, and the coat ruptures to release in a pulse the therapeutically active agent in a reliable manner at about a predetd. time; the reliable manner of rupture comprises rupturing of 36 **tablets** out of a total of 36 **tablets** at about the predetd. time when tested by subjecting the **tablets** to USP dissoln. test using an aq. media at 37.degree., in a USP Type I or Type II app. at about 50-100 rpm. For example, a timed pulse release **tablet** was prepd. contg. (as core) **metformin** hydrochloride 500.0 mg, AcDiSol 50.0 mg, corn starch (10% starch paste) 17.0 mg, microcryst. **cellulose** 13.5 mg, colloidal silica 13.5 mg, and magnesium stearate 6.0 mg, and (as a coat) Et **cellulose** 40.7 mg, and hydroxypropyl Me **cellulose** 16.3 mg. **Tablets** released the **metformin** as a pulse after the rupture of the coat at a predetd. time (about 1-1.3 h).

L19 ANSWER 65 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:284364 HCAPLUS
DOCUMENT NUMBER: 138:44601
TITLE: Functionality testing of a multifunctional directly compressible adjuvant containing lactose, polyvinylpyrrolidone, and **croscarmellose** sodium
AUTHOR(S): Gohel, Mukesh C.; Jogani, Pranav D.
CORPORATE SOURCE: Lallubhai Motilal College of Pharmacy, Ahmedabad, 380 009, India
SOURCE: Pharmaceutical Technology North America (2002), 26(3), 64,66,68,70,72,74,76,78,80,82
CODEN: PTNABQ; ISSN: 1534-2131
PUBLISHER: Advanstar Communications, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A directly compressible multifunctional adjuvant contg. lactose, polyvinylpyrrolidone, and **croscarmellose** sodium was prepd. by using a simple solvent-free method. The flowability and compressibility of the agglomerates obtained were significantly superior to those of lactose monohydrate. The agglomerates exhibited good diln. potential and were sensitive to high humidity. **Tablets** prepd. by using herbal drugs (Glycyrrhiza and turmeric) and synthetic drugs such as **metformin**-HCl and acetaminophen were satisfactory.

L19 ANSWER 66 OF 256 USPATFULL on STN
ACCESSION NUMBER: 1999:78774 USPATFULL
TITLE: Glibenclamide-**metformin** combination for the treatment of diabetes mellitus of type II
INVENTOR(S): Barelli, Giulio, Pisa, Italy
De Regis, Massimo, Pisa, Italy
PATENT ASSIGNEE(S): Abiogen Pharma s.r.l., Italy (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5922769		19990713	
	WO 9717975		19970522	
APPLICATION INFO.:	US 1998-29371		19980513	(9)

WO 1996-EP4860 19961107
19980513 PCT 371 date
19980513 PCT 102(e) date

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1995-MI2337	19951114

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Henley, III, Raymond
LEGAL REPRESENTATIVE: Nixon & Vanderhye
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
LINE COUNT: 509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Non-insulin dependent diabetes mellitus in cases of secondary failure is treated with a combination of glibenclamide and **metformin**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 67 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:180234 USPATFULL
TITLE: Pharmaceutical safety dosage forms
INVENTOR(S): Roberts, Richard H., Lakewood, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003124061	A1	20030703	
APPLICATION INFO.:	US 2003-339977	A1	20030110	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WOODCOCK WASHBURN LLP, ONE LIBERTY PLACE, 46TH FLOOR, 1650 MARKET STREET, PHILADELPHIA, PA, 19103
NUMBER OF CLAIMS: 228
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Page(s)
LINE COUNT: 1140
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical safety dosage forms are provided which include a pharmaceutical and an antagonist to the pharmaceutical. The safety dosage forms are such that the antagonist has no significant bioavailability when the pharmaceutical safety dosage form is administered as intended. However, the antagonist is released and becomes bioavailable if the dosage form is disrupted. Methods of administering pharmaceuticals by providing pharmaceutical safety dosage forms are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 68 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:114962 HCAPLUS
DOCUMENT NUMBER: 134:152671
TITLE: Floating pharmaceutical composition comprising an active phase and a non-active phase
INVENTOR(S): Besse, Jerome
PATENT ASSIGNEE(S): Galenix Developpement, Fr.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2001010417	A1	20010215	WO 2000-FR2223	20000802	
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG					
FR 2797185	A1	20010209	FR 1999-10285	19990806	
FR 2797185	B1	20011026			
EP 1206247	A1	20020522	EP 2000-956599	20000802	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
BR 2000013106	A	20020723	BR 2000-13106	20000802	
NO 2002000572	A	20020403	NO 2002-572	20020205	
PRIORITY APPLN. INFO.:			FR 1999-10285	A 19990806	
			WO 2000-FR2223	W 20000802	

AB The invention concerns a floating pharmaceutical compn. consisting of at least a first phase comprising at least a high dose active principle combined with one or several carriers and at least a second phase comprising at least a gas-generating system. The invention also concerns **tablets** comprising such a pharmaceutical compn. and a method for prepg. such **tablets**. A programmed-release **tablet** contained **metformin** hydrochloride 51.33, Carbopol-974 3.02, hydroxypropyl **cellulose** 4.53, magnesium stearate 0.06% in the active layer; and hydroxypropylmethyl **cellulose** 24.64, monosodium citrate 7.23 in the non-active layer.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 69 OF 256 USPATFULL on STN

ACCESSION NUMBER: 2003:201447 USPATFULL

TITLE: Combinations comprising dipeptidylpeptidase-iv inhibitor

INVENTOR(S): Balkan, Bork, Madison, CT, UNITED STATES
Hughes, Thomas Edward, Somerville, NJ, UNITED STATES
Holmes, David Grenville, Binningen, SWITZERLAND
Villhauer, Edwin Bernard, Morristown, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003139434	A1	20030724	
APPLICATION INFO.:	US 2002-181169	A1	20021010	(10)
	WO 2001-EP590		20010119	

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-9489234	20000121
	US 2000-9619262	20000719

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THOMAS HOXIE, NOVARTIS, PATENT AND TRADEMARK DEPARTMENT, ONE HEALTH PLAZA 430/2, EAST HANOVER, NJ, 07936-1080
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
LINE COUNT: 1581
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway

modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, .alpha.-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and .alpha..sub.2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 70 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2000:716155 HCAPLUS
DOCUMENT NUMBER: 134:285541
TITLE: New excipients in fast-release **tablet** formulations
AUTHOR(S): Fang, Xiao-Ling; Yang, Min; Mu, Ni-La; Wang, Xue-Liang; Zhang, Jin
CORPORATE SOURCE: Dept. of Pharmaceutics, Shanghai Medical University, Shanghai, 200032, Peop. Rep. China
SOURCE: Zhongguo Yiyao Gongye Zazhi (2000), 31(6), 257-259
CODEN: ZYGZEA; ISSN: 1001-8255
PUBLISHER: Zhongguo Yiyao Gongye Zazhi Bianjibu
DOCUMENT TYPE: Journal
LANGUAGE: Chinese
AB The water-sol. but poor-compressible drug **metformin**-HCl and the poor water-sol. but good-compressible drug ofloxacin were chosen as model drugs for test. The formulations were designed and evaluated using super-disintegrants (crosslinking PVP, crosslinking CMC-Na, L-HPC and CMS-Na), new binder PVP, and new filler microcryst. **cellulose**. The quality criteria such as granular property, compressibility, disintegration time and dissoln. for various formulations indicated that these new excipients could be used satisfactorily in fast-release **tablets** formulation.

L19 ANSWER 71 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:40435 USPATFULL
TITLE: Oral formulation comprising biguanide and an organic acid
INVENTOR(S): Nishii, Hiroyuki, Osaka, JAPAN
Kobayashi, Hirohisa, Osaka, JAPAN
Otoda, Kazuya, Takarazuka, JAPAN
PATENT ASSIGNEE(S): Sumitomo Pharmaceuticals Company, Limited, Osaka, JAPAN (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6517870	B1	20030211	
	WO 9955320		19991104	
APPLICATION INFO.:	US 2000-674150		20001027	(9)
	WO 1999-JP2192		19990426	

NUMBER DATE

PRIORITY INFORMATION:	JP 1998-136126	19980429
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Spear, James M.	
LEGAL REPRESENTATIVE:	Birch, Stewart, Kolasch & Birch, LLP	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	302	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An oral formulation comprising a biguanide and an organic acid has less unpleasant tastes such as bitterness and saltiness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 72 OF 256 USPATFULL on STN

ACCESSION NUMBER:	2001:193965 USPATFULL		
TITLE:	Core formulation		
INVENTOR(S):	Adjei, Akwete L., Bridgewater, NJ, United States Zhu, Yaping, Highland Park, International Patent Institute Cutie, Anthony J., Bridgewater, International Patent Institute		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001036478	A1	20011101
	US 6461639	B2	20021008
APPLICATION INFO.:	US 2001-783810	A1	20010215 (9)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2000-201233P		20000501 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Jerome Rosenstock, Frommer Lawrence & Haug LLP, 745 Fifth Avenue, New York, NY, 10151		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
LINE COUNT:	532		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to a controlled-release combination drug product comprising troglitazone, e.g. its hydrochloride, and a biguamide, e.g. **metformin**. In particular, the product comprises a core of **metformin**, at least a portion thereof has a layer or coat thereon of troglitazone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 73 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:	2003:609873 HCAPLUS
DOCUMENT NUMBER:	139:154910
TITLE:	Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
INVENTOR(S):	Lim, Jong C.; Shell, John N.
PATENT ASSIGNEE(S):	Depomed, Inc., USA
SOURCE:	U.S. Pat. Appl. Publ., 5 pp. CODEN: USXXCO
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003147952	A1	20030807	US 2002-66146	20020201
WO 2003066028	A1	20030814	WO 2003-US2809	20030128

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-66146 A 20020201

AB A method is disclosed for manufg. a pharmaceutical **tablet** for oral administration, the **tablet** combining both immediate-release and prolonged-release modes of drug delivery and using an immediate-release drug that is either insol. in water or only sparingly sol. and is present in a very small amt. compared to the prolonged-release drug. The method involves the use of particles of the immediate-release drug that are equal to or less than 10 .mu. in diam., applied as a layer or **coating** over a core of the prolonged-release drug, the layer or **coating** being either the drug particles themselves, applied as an aq. suspension, or a solid mixt. contg. the drug in admixt. with a material that disintegrates rapidly in gastric fluid. The result in both cases is a high degree of uniformity in the proportions of the immediate-release and prolonged-release drugs, uniformity that is otherwise difficult to achieve in view of the insoly. of the immediate-release drug and its relatively small amt. compared to the prolonged-released drug. **Tablets** contg. **metformin**-HCl and glimepiride were prepd. contg. HPMC and PEG, using Polysorbate 80 solns.

L19 ANSWER 74 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1987:605192 HCAPLUS

DOCUMENT NUMBER: 107:205192

TITLE: N,N-**dimethylbiguanide** p-chlorophenoxyacetate pharmaceutical preparation for treatment of neuropathies

INVENTOR(S): Hugelin, Andre; Thal, Claude

PATENT ASSIGNEE(S): Fr.

SOURCE: Fr. Demande, 8 pp.
CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2585572	A1	19870206	FR 1985-11664	19850731
FR 2585572	B1	19871231		
AU 8660768	A1	19870205	AU 1986-60768	19860731
AU 587054	B2	19890803		
EP 214017	A2	19870311	EP 1986-401717	19860731
EP 214017	A3	19890726		
EP 214017	B1	19920722		

R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE

JP 62116510	A2	19870528	JP 1986-181195	19860731
JP 07025671	B4	19950322		
ZA 8605735	A	19871125	ZA 1986-5735	19860731
AT 78397	E	19920815	AT 1986-401717	19860731

US 4835184 A 19890530 US 1986-893025 19860801
PRIORITY APPLN. INFO.: FR 1985-11664 19850731
EP 1986-401717 19860731

AB Neurotrophic pharmaceuticals contain a neurol. active quantity of N,N-**dimethylbiguanide** p-chlorophenoxyacetate (I). Effervescent **tablets** contained I 1500, corn starch 24, wheat starch 36, lactose 375, NaHCO3 12.6, tartaric acid 11.25, hydroxypropyl **cellulose** 18, Povidone C15 12, and a sugar glaze 120 mg. I was as effective as Isaxonine in regeneration of nerve fibers in rats, whereas N,N-**dimethylbiguanide**-HCl was ineffective.

L19 ANSWER 75 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2001:188740 USPATFULL
TITLE: Core formulation
INVENTOR(S): Adjei, Akwete L., Bridgewater, NJ, United States
Zhu, Yaping, Highland Park, NJ, United States
Cutie, Anthony J., Bridgewater, NJ, United States

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001034374	A1	20011025
	US 6451342	B2	20020917
APPLICATION INFO.:	US 2001-784288	A1	20010215 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201233P	20000501 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Jerome Rosenstock, Esq, c/o FROMMER LAWRENCE & HAUG LLP, 745 Fifth Avenue, New York, NY, 10151
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 544
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to a controlled release combination drug product comprising troglitazone, e.g. its hydrochloride, and a biguamide, e.g. **metformin**. In particular, the product comprises a core of **metformin**, at least a portion thereof has a layer or coat thereon of troglitazone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 76 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2002:136590 USPATFULL
TITLE: Core formulation
INVENTOR(S): Adjei, Akwete L., Bridgewater, NJ, United States
Zhu, Yaping, Highland Park, NJ, United States
Cutie, Anthony J., Bridgewater, NJ, United States
PATENT ASSIGNEE(S): Aeropharm Technology Incorporated, Edison, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6403121	B1	20020611
APPLICATION INFO.:	US 2001-783783		20010215 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201057P	20000501 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Henley, III, Raymond
LEGAL REPRESENTATIVE: Frommer Lawrence & Haug LLP

NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 0 Drawing Figure(s); 0 Drawing Page(s)
LINE COUNT: 493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to a modulating formulation comprising pioglitazone hydrochloride and a biguamide, e.g. **metformin**. In particular, the product comprises a core of the biguamide, e.g. **metformin**, at least a portion thereof has a layer or coat thereon of pioglitazone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 77 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2001:218028 USPATFULL
TITLE: Core formulation
INVENTOR(S): Adjei, Akwete L., Bridgewater, NY, United States
Zhu, Yaping, Highland Park, NJ, United States
Cutie, Anthony J., Bridgewater, NJ, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001046515	A1	20011129	
	US 6524621	B2	20030225	
APPLICATION INFO.:	US 2001-784713	A1	20010215	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201057P	20000501 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: JEROME ROSENSTOCK, FROMMER LAWRENCE & HAUG LLP, 745 Fifth Avenue, New York, NY, 10151
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
LINE COUNT: 493
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to a modulating formulation comprising pioglitazone hydrochloride and a biguamide, e.g. **metformin**. In particular, the product comprises a core of the biguamide, e.g. **metformin**, at least a portion thereof has a layer or coat thereon of pioglitazone. PATENT

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 78 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2001:29618 USPATFULL
TITLE: Use of **metformin** to counteract weight gain associated with valproate and other psychotropic medications
INVENTOR(S): Cottingham, Elizabeth Marie, 300 Warren Ave., Cincinnati, OH, United States 45219
Morrison, John Ainslie, 3740 Clifton Ave., Cincinnati, OH, United States 45220

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6194466	B1	20010227	
APPLICATION INFO.:	US 1999-416330		19991012	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-104394P	19981015 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: Granted
PRIMARY EXAMINER: Criares, Theodore J.
ASSISTANT EXAMINER: Kim, J.
LEGAL REPRESENTATIVE: Frost Brown Todd LLC
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
LINE COUNT: 224
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for minimizing the weight gain side effect associated with Valproate treatment is disclosed. In this method, **Metformin**, a biguanide compound, is concurrently administered to a patient taking the Valproate therapy. A pharmaceutical composition containing the combination of Valproate and **Metformin** is also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 79 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2001:167766 USPATFULL
TITLE: Core formulation comprising troglitazone and abiguanide
INVENTOR(S): Cutie, Anthony J., Bridgewater, NJ, United States
Adjei, Akwete L., Bridgewater, NJ, United States
PATENT ASSIGNEE(S): Aeropharm Technology Incorporated, Edison, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6296874	B1	20011002
APPLICATION INFO.:	US 2000-703023		20001031 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-201233P	20000501 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Spear, James M.
LEGAL REPRESENTATIVE: Frommer Lawrence & Haug LLP
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
LINE COUNT: 384
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to a combination drug product comprising troglitazone, e.g. its hydrochloride, and a biguamide, e.g. **metformin**. In particular, the product comprises a core of **metformin**, at least a portion thereof has a layer or coat thereon of troglitazone.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 80 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:391499 HCAPLUS
DOCUMENT NUMBER: 136:406855
TITLE: Medicine based on antihyperglycemic microcapsules with prolonged release and method for preparing same
INVENTOR(S): Castan, Catherine; Meyrueix, Remi; Soula, Gerard
PATENT ASSIGNEE(S): Flamel Technologies, Fr.
SOURCE: PCT Int. Appl., 28 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2002039984 A2 20020523 WO 2001-FR3625 20011119
WO 2002039984 A3 20020711
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
FR 2816840 A1 20020524 FR 2000-14876 20001117
AU 2002020796 A5 20020527 AU 2002-20796 20011119
EP 1333816 A2 20030813 EP 2001-996365 20011119
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.: FR 2000-14876 A 20001117
WO 2001-FR3625 W 20011119

AB The invention concerns an oral galenic form for prolonged release of anti-hyperglycemic (**metformin**) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 h by overcoming the problems of bypass of the absorption window and the massive localized release of active principles. Therefor, said medicine comprises several thousand anti- hyperglycemic (**metformin**) microcapsules each consisting of a core comprising at least an anti- hyperglycemic agent and of a **coating** film applied on the core and enabling the prolonged release in vivo of the anti- hyperglycemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 .mu.. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycemic or hypoglycemic. The invention also concerns the prepn. of said medicine and the use of a plurality of said microcapsules for making an anti- hyperglycemic medicine. The invention is applicable to the treatment of type II diabetes. A soln. of 159.5 g stearic acid and 159.5 g Et **cellulose** in 2870 g isopropanol at 50.degree. was sprayed on 700 g of **metformin** hydrochloride crystals (av. diam. 100-200 .mu.m). The dissoln. rate of the granules thus obtained was 97.1% after 20 min.

L19 ANSWER 81 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2001:152504 USPATFULL
TITLE: Pharmaceutical compositions of vanadium biguanide complexes and their use
INVENTOR(S): Orvig, Chris, Vancover, Canada
McNeill, John H., Vancouver, Canada
PATENT ASSIGNEE(S): The University of British Columbia, Vancouver, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6287586	B1	20010911
APPLICATION INFO.:	US 1999-396982		19990915 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-101074P	19980918 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Webman, Edward J.
ASSISTANT EXAMINER: Nguyen, Helen
LEGAL REPRESENTATIVE: Sherwood, Pamela J.Bozicevic, Field & Francis LLP
NUMBER OF CLAIMS: 10
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)

LINE COUNT: 798
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Pharmaceutical compositions of vanadium biguanide complexes, and methods of use, are provided for the treatment of hyperglycemia and related disorders, e.g. hypertension, obesity, and lipid disturbances. The pharmaceutically active complexes of the invention comprise a biguanide chelant, preferably a 1-substituted biguanide chelant, capable of chelating vanadium to form a six-membered unsaturated vanadium-containing ring. The vanadium of the complex is coordinated with oxygen, sulphur or nitrogen, particularly oxygen coordinated. The complexes are formulated with a physiologically acceptable carrier. In a preferred embodiment, the complexes are formulated for oral administration.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 82 OF 256 USPATFULL on STN
ACCESSION NUMBER: 75:21254 USPATFULL
TITLE: Antihyperglycemic methods and compositions
INVENTOR(S): Kabbe, Hans-Joachim, Leverkusen, Germany, Federal Republic of
Horstmann, Harald, Wuppertal-Elberfeld, Germany, Federal Republic of
Plumpe, Hans, Wuppertal-Elberfeld, Germany, Federal Republic of
Puls, Walter, Wuppertal-Elberfeld, Germany, Federal Republic of
Petersen, Siegfried, Leverkusen, Germany, Federal Republic of
PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Leverkusen, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 3879541		19750422
APPLICATION INFO.:	US 1973-324218		19730116 (5)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1971-118958, filed on 25 Feb 1971, now abandoned And Ser. No. US 1971-120332, filed on 2 Mar 1971, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1970-2009738	19700303
	DE 1970-2009743	19700303

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Waddell, Frederick E.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 470
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The blood sugar level of hyperglycemic animals can be reduced through administration of an N.sup.1 -phenylbiguanide which is substituted in the N.sup.5 -position by the group CH.sub.2 R.sup.2 in which R.sup.2 is hydrogen, alkyl of 1 to 7 carbon atoms, alkoxyalkyl of 2 to 5 carbon atoms, cyclohexyl or vinyl, and optionally substituted by one or two groups in the phenyl ring. Solid, orally administered pharmaceutical compositions are also described. A typical embodiment is the use of N.sup.1 -(4-chlorophenyl)-N.sup.5 -(n-propyl)biguanide hydrochloride which can be administered in a **tablet**, **capsule** or dragee.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 83 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:237424 USPATFULL
TITLE: Compositions for treating diabetes mellitus, methods of use and manufacturing process of the same
INVENTOR(S): Wang, Peng, Burlingame, CA, UNITED STATES
Lei, Lin, Melshan, CHINA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003165581	A1	20030904	
APPLICATION INFO.:	US 2002-91371	A1	20020304	(10)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILSON SONSINI GOODRICH & ROSATI, 650 PAGE MILL ROAD, PALO ALTO, CA, 943041050
NUMBER OF CLAIMS: 64
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 1044
AB The present invention provides novel compositions and methods for lowering blood glucose levels, as well as manufacture processes for producing the compositions. Specifically, the present invention provides novel compositions that are extracts of the plant Prunella Linn and/or Rabdosis (Blume) Hasskarl containing enriched corosolic acid. Methods of isolating corosolic acid at high purity from these plants are also provided. These extracts and the purified corosolic acid can be used for lowering blood sugar levels and reducing accumulation of triglyeride in the treatment of diabetes, obesity and related conditions.

L19 ANSWER 84 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:159938 USPATFULL
TITLE: Treatment of diabetes with thiazolidinedione and **metformin**
INVENTOR(S): Smith, Stephen Alistair, Bramfield, UNITED KINGDOM
PATENT ASSIGNEE(S): SmithKline Beecham plc (non-U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003109553	A1	20030612	
APPLICATION INFO.:	US 2003-340426	A1	20030110	(10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2002-99161, filed on 13 Mar 2002, ABANDONED Continuation of Ser. No. US 2001-925394, filed on 9 Aug 2001, ABANDONED Continuation of Ser. No. US 1999-446030, filed on 15 Dec 1999, ABANDONED A 371 of International Ser. No. WO 1998-EP3690, filed on 15 Jun 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-12857	19970618
	GB 1998-6706	19980327

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 484
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin

sensitiser and a biguanide antihyperglycaemic agent, to a mammal in need thereof and a pharmaceutical composition comprising an insulin sensitiser and a biguanide antihyperglycaemic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 85 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2002:251818 USPATFULL
TITLE: Treatment of diabetes with thiazolidinedione and **metformin**
INVENTOR(S): Smith, Stephen Alistair, Bramfield, UNITED KINGDOM
PATENT ASSIGNEE(S): SmithKline Beecham plc (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002137772	A1	20020926
APPLICATION INFO.:	US 2002-99161	A1	20020313 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 2001-925394, filed on 9 Aug 2001, ABANDONED Continuation of Ser. No. US 1999-446030, filed on 15 Dec 1999, ABANDONED A 371 of International Ser. No. WO 1998-EP3690, filed on 15 Jun 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-12857	19970618
	GB 1998-6706	19980327

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 485
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and a biguanidine antihyperglycaemic agent, to a mammal in need thereof and a pharmaceutical composition comprising an insulin sensitiser and a biguanide antihyperglycaemic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 86 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2002:8515 USPATFULL
TITLE: Treatment of diabetes with thiazolidinedione and **metformin**
INVENTOR(S): Smith, Stephen Alistair, Bramfield, UNITED KINGDOM

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002004515	A1	20020110
APPLICATION INFO.:	US 2001-925394	A1	20010809 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-446030, filed on 15 Dec 1999, ABANDONED A 371 of International Ser. No. WO 1998-EP3690, filed on 15 Jun 1998, UNKNOWN

	NUMBER	DATE
PRIORITY INFORMATION:	GB 1997-12857	19970618
	GB 1998-6706	19980327

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: GLAXOSMITHKLINE, Corporate Intellectual Property - UW2220, P.O. Box 1539, King of Prussia, PA, 19406-0939
NUMBER OF CLAIMS: 22
EXEMPLARY CLAIM: 1
LINE COUNT: 484
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and a biguanidine antihyperglycaemic agent, to a mammal in need thereof and a pharmaceutical composition comprising an insulin sensitiser and a biguanide antihyperglycaemic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 87 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2002:54399 USPATFULL
TITLE: Preparation of aqueous clear solution dosage forms with bile acids
INVENTOR(S): Yoo, Seo Hong, Wyckoff, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002031558	A1	20020314
APPLICATION INFO.:	US 2001-778154	A1	20010205 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-357549, filed on 20 Jul 1999, GRANTED, Pat. No. US 6251428

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-94069P	19980724 (60)
	US 2000-180268P	20000204 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: BAKER BOTTS L.L.P., 44TH FLOOR, 30 ROCKEFELLER PLAZA, NEW YORK, NY, 10112-4498
NUMBER OF CLAIMS: 87
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 12 Drawing Page(s)
LINE COUNT: 2250
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions for pharmaceutical and other uses comprising clear aqueous solutions of bile acids which do not form any detectable precipitates over selected ranges of pH values of the aqueous solution and methods of making such solutions. The compositions of the invention comprise water; a bile acid in the form of a bile acid, bile acid salt, or a bile acid conjugated with an amine by an amide linkage; and either or both an aqueous soluble starch conversion product and an aqueous soluble non-starch polysaccharide. The composition remains in solution without forming a precipitate over a range of pH values and, according to one embodiment, remains in solution for all pH values obtainable in an aqueous system. The composition, according to some embodiments, may further contain a pharmaceutical compound in a pharmaceutically effective amount. Non-limiting examples of pharmaceutical compounds include insulin, heparin, bismuth compounds, amantadine and rimantadine.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 88 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:228693 HCAPLUS
DOCUMENT NUMBER: 134:256878
TITLE: Pharmaceuticals containing nateglinide or repaglinide

for treating diabetes or conditions assocd. with diabetes
INVENTOR(S): Gatlin, Marjorie Regan; Pongowski, Michele; Mannion, Richard Owen; Karnachi, Anees Abdulquadar; Guitard, Christiane; Allison, Malcolm
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis-Erfindungen Verwaltungsgesellschaft m.b.H.
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021159	A2	20010329	WO 2000-EP9074	20000915
WO 2001021159	A3	20011227		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2798592	A1	20010323	FR 2000-11782	20000915
BR 2000014525	A	20020611	BR 2000-14525	20000915
EP 1212077	A2	20020612	EP 2000-969260	20000915
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BE 1013726	A5	20020702	BE 2000-585	20000915
JP 2003509457	T2	20030311	JP 2001-524585	20000915
US 6559188	B1	20030506	US 2000-663264	20000915
FI 2001000683	A	20010402	FI 2001-683	20010402
NO 2002001197	A	20020516	NO 2002-1197	20020311
US 2003162816	A1	20030828	US 2003-345908	20030116

PRIORITY APPLN. INFO.:

US 1999-242911P	P	19990917
US 1999-398364	A	19990917
US 2000-240918P	P	20000309
US 2000-304196P	P	20000407
US 2000-545480	A	20000407
GB 2000-21055	A	20000826
US 1999-240911P	P	19990917
US 2000-521737	A	20000309
US 2000-663264	A1	20000915
WO 2000-EP9074	W	20000915

AB The invention relates to a combination, such as a combined prepn. or pharmaceutical compn., resp., which comprises nateglinide or repaglinide and at 1 other antidiabetic compd. selected from the group consisting of thiazolidinedione derivs. (glitazones), sulfonylurea derivs. and **metformin** for simultaneous, sep. or sequential use in the prevention, delay of progression or treatment of the diseases. The compn. is esp. useful for the treatment of type 2 diabetes and diseases. Thus, **tablet** contained nateglinide 12.960, lactose 30.564, microcryst. **cellulose** 15.336, povidone 2.592, **croscarmellose** sodium 3.974, colloidal SiO2 1.382, magnesium stearate 1.231, and **coating** with **Opadry** yellow 1.944 kg., and water qs.

L19 ANSWER 89 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2002:112964 USPATFULL
TITLE: COMPOSITIONS CONTAINING HYPOGLYCEMICALLY ACTIVE STILBENOIDS

INVENTOR(S): Hopp, David C., Mill Creek, WA, UNITED STATES
Inman, Wayne D., Belmont, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002058707	A1	20020516
	US 6410596	B2	20020625
APPLICATION INFO.:	US 2001-919966	A1	20010802 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225800P	20000816 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2015
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as hypoglycemic agents or to lower serum glucose levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypoglycemic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 90 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2002:112958 USPATFULL
TITLE: Compositions containing hypoglycemically active stilbenoids
INVENTOR(S): Inman, Wayne D., Belmont, CA, UNITED STATES
Hopp, David C., Mill Creek, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002058701	A1	20020516
	US 6552085	B2	20030422
APPLICATION INFO.:	US 2001-919883	A1	20010802 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-225665P	20000816 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: STERNE, KESSLER, GOLDSTEIN & FOX PLLC, 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Page(s)
LINE COUNT: 2013
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The use of isolated or purified stilbenoid compounds including longistyline A-2-carboxylic acid as hypoglycemic agents or to lower serum glucose levels is described. The invention also relates to the use of such stibenoid compounds in combination with other hypoglycemic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 91 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1999:549136 HCAPLUS

DOCUMENT NUMBER: 131:161654
TITLE: Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent
INVENTOR(S): Saslawski, Olivier; Giet, Philippe; Michel, Dominique; Hulot, Thierry
PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9942086	A1	19990826	WO 1999-EP994	19990216
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2775188	A1	19990827	FR 1998-2143	19980223
FR 2775188	B1	20010309		
CA 2321267	AA	19990826	CA 1999-2321267	19990216
AU 9931408	A1	19990906	AU 1999-31408	19990216
AU 750785	B2	20020725		
BR 9908121	A	20001024	BR 1999-8121	19990216
EP 1056445	A1	20001206	EP 1999-913165	19990216
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
JP 2002503686	T2	20020205	JP 2000-532103	19990216
ZA 9901408	A	19990823	ZA 1999-1408	19990222
NO 2000004190	A	20001020	NO 2000-4190	20000822
US 6426087	B1	20020730	US 2000-622663	20000822
US 6514524	B1	20030204	US 2002-100084	20020319

PRIORITY APPLN. INFO.:
FR 1998-2143 A 19980223
WO 1999-EP994 W 19990216
US 2000-622633 A1 20000822

OTHER SOURCE(S): MARPAT 131:161654

AB The present invention relates to an orally administrable galenic form allowing improved absorption by the transmembrane or paracellular route in the gastrointestinal tract of active ingredients which are hydrophilic or ionizable in physiol. media, comprising at least one such active ingredient, an absorption-promoting agent having an HLB >8, the the absorption-promoting agent consisting of one or more lipid substances chosen from: polysorbates; polyoxyethylene ethers; esters of polyoxyethylene and fatty acids; fatty acids; fatty alcs.; bile acids and their salts with pharmaceutically acceptable cations; esters of C1-C6 alkanol with fatty acids; esters of polyol with fatty acids, the polyol comprising from 2 to 6 hydroxyl functional groups; and polyglycolyzed glycerides; in combination with one or more pharmaceutically acceptable excipients, the pharmaceutical forms comprising captopril being excluded. A controlled-release **tablet** contained (1) cores contg. calcium acamprosate 50, Gelucire 44/14 10, Compritol 10, microcryst. **cellulose** 19, Povidone 10, and Mg stearate 1 % and (2) a film-**coating** compn. contg. HPMC 64, PEG-4000 15, and talc 21 %.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 92 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:472994 HCAPLUS
DOCUMENT NUMBER: 139:41844
TITLE: Reverse micellar delivery system for controlled transport and enhanced drug absorption
INVENTOR(S): MacGregor, Alexander
PATENT ASSIGNEE(S): Can.
SOURCE: U.S. Pat. Appl. Publ., 16 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003113366	A1	20030619	US 2001-24325	20011214
WO 2003051333	A1	20030626	WO 2002-CA1918	20021213

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2001-24325 A 20011214
AB The present invention provides a reverse-micellar delivery system for enhanced absorption of an agent of interest across biol. membranes such as the gastro-intestinal tract of mammals. The reverse-micelles comprise at least one ionic amphipathic compd., and at least one polar active agent ionizable in aq. or physiol. media. The delivery system facilitates transportation of the agent across the gastro-intestinal tract or other membranes and enhances the in-vivo release and availability of the agent(s) of interest within a fluid environment. An extended release **tablet** contained **metformin**-HCl 69, cetyl alc. 18, Na lauryl sulfate 10, Et **cellulose** 2, and Mg stearate 1%/ **tablet**.

L19 ANSWER 93 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2001:163422 HCAPLUS
DOCUMENT NUMBER: 134:212730
TITLE: Controlled-release lipoic acid
INVENTOR(S): Byrd, Edward A.; Janjikhel, Rajiv
PATENT ASSIGNEE(S): Medical Research Institute, USA
SOURCE: U.S., 14 pp., Cont.-in-part of U.S. Ser. No. 112,623, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6197340	B1	20010306	US 1999-288245	19990408
US 6191162	B1	20010220	US 1999-288253	19990408
CA 2332790	AA	19991202	CA 1999-2332790	19990519
WO 9961004	A1	19991202	WO 1999-US11178	19990519

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,

JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD,
RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9940903	A1	19991213	AU 1999-40903	19990519
EP 1082107	A1	20010314	EP 1999-924394	19990519
R: DE, ES, FR, GB, IT				
JP 2002516270	T2	20020604	JP 2000-550464	19990519
US 2001028896	A1	20011011	US 2001-755890	20010105
US 6572888	B2	20030603		
US 2003039690	A1	20030227	US 2002-226646	20020823

PRIORITY APPLN. INFO.:	US 1998-87203P	P	19980528
	US 1998-112623	B2	19980709
	US 1998-102605P	P	19981001
	US 1999-288245	A	19990408
	WO 1999-US11178	W	19990519
	US 2001-755890	A2	20010105

AB A controlled release formulation of lipoic acid is disclosed. The lipoic acid is combined with excipient materials in such a way that those materials protect the lipoic acid from chem. degrdn. in the gastrointestinal tract and provide for gradual release of the lipoic acid. These combined features make it possible to use lipoic acid to reduce serum glucose levels and maintain those levels over time thereby obtaining a range of desired results. A sustained-release **tablet** contained racemic .alpha.-lipoic acid coated particles 81, Methocel K100 10, microcryst. **cellulose** 5, stearic acid 3, micronized silica 0.5, and magnesium stearate 0.5%. Efficacy of the formulation in lowering blood glucose level of patients is reported.

REFERENCE COUNT: 115 THERE ARE 115 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 94 OF 256 USPATFULL on STN

ACCESSION NUMBER:	2003:24185 USPATFULL
TITLE:	Combination therapy for type II diabetes or Syndrome X
INVENTOR(S):	Gwynne, John Thomas, Doylestown, PA, UNITED STATES Vitou, Philippe John Robert, Paris, FRANCE Randazzo, Bruce Paul, Rydal, PA, UNITED STATES
PATENT ASSIGNEE(S):	Wyeth, Madison, NJ (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003018028	A1	20030123	
APPLICATION INFO.:	US 2002-163707	A1	20020606	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-296502P	20010607 (60)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Arnold S. Milowsky, 5 Giralda Farms, Madison, NJ, 07940
NUMBER OF CLAIMS:	23
EXEMPLARY CLAIM:	1
LINE COUNT:	1108

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods of using a pharmacological combination of a biguanide agents, such as **metformin**, and one or more PTPase inhibiting agents and, optionally, one or more sulfonylurea agents, including glyburide, glyburide, glipizide, glimepiride, chlorpropamide, tolbutamide, or tolazamide, for treatment in a mammal of Syndrome X, type II diabetes or metabolic disorders mediated by insulin

resistance or hyperglycemia. Further included in this invention is a method of modulating blood glucose levels in a mammal utilizing the combination of one or more PTPase inhibiting agents and one or more sulfonlylurea agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 95 OF 256 USPATFULL on STN
ACCESSION NUMBER: 1999:160079 USPATFULL
TITLE: Glycogen phosphorylase inhibitors
INVENTOR(S): Hulin, Bernard, Essex, CT, United States
Sarges, Reinhard, Mystic, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5998463		19991207	
APPLICATION INFO.:	US 1999-251141		19990216	(9)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1998-76132P	19980227	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Keating, Dominic
LEGAL REPRESENTATIVE: Richardson, Peter C., Benson, Gregg C., Gammill, Martha A.
NUMBER OF CLAIMS: 23
EXEMPLARY CLAIM: 1
LINE COUNT: 1835
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to certain 5-acyl-2-oxo-indole-3-carboxamides useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds. This invention also relates to pharmaceutical compositions comprising those 5-acyl-2-oxo-indole-3-carboxamides in combination with antidiabetes agents and methods of treating glycogen phosphorylase dependent diseases or conditions with such compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 96 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:79163 USPATFULL
TITLE: Combination therapy comprising glucose reabsorption inhibitors and retinoid-X receptor modulators
INVENTOR(S): Bussolari, Jacqueline C., Skillman, NJ, UNITED STATES
Chen, Xiaoli, Belle Mead, NJ, UNITED STATES
Conway, Bruce R., Doylestown, PA, UNITED STATES
Demarest, Keith T., Flemington, NJ, UNITED STATES
Ross, Hamish N.M., Far Hills, NJ, UNITED STATES
Severino, Rafael, Madrid, SPAIN

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003055091	A1	20030320	
APPLICATION INFO.:	US 2002-115725	A1	20020403	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-281479P	20010404	(60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
NUMBER OF CLAIMS: 79
EXEMPLARY CLAIM: 1
LINE COUNT: 2308
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Combination therapy comprising RXR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 97 OF 256 USPATFULL on STN
ACCESSION NUMBER: 2003:65429 USPATFULL
TITLE: Combination therapy comprising glucose reabsorption inhibitors and PPAR modulators
INVENTOR(S): Bussolari, Jacqueline C., Skillman, NJ, UNITED STATES
Chen, Xiaoli, Belle Mead, NJ, UNITED STATES
Conway, Bruce R., Doylestown, PA, UNITED STATES
Demarest, Keith T., Flemington, NJ, UNITED STATES
Ross, Hamish N.M., Far Hills, NJ, UNITED STATES
Severino, Rafael, Madrid, SPAIN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003045553	A1	20030306
APPLICATION INFO.:	US 2002-115827	A1	20020403 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-281429P	20010404 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: AUDLEY A. CIAMPORCERO JR., JOHNSON & JOHNSON, ONE JOHNSON & JOHNSON PLAZA, NEW BRUNSWICK, NJ, 08933-7003
NUMBER OF CLAIMS: 67
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Page(s)
LINE COUNT: 2106
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Combination therapy comprising PPAR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L19 ANSWER 98 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 1998:804171 HCAPLUS
DOCUMENT NUMBER: 130:57204
TITLE: Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
INVENTOR(S): Shell, John W.; Louie-Helm, Jenny
PATENT ASSIGNEE(S): Depomed, Inc., USA
SOURCE: PCT Int. Appl., 31 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9855107	A1	19981210	WO 1998-US11302	19980605

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

AU 9881386	A1	19981221	AU 1998-81386	19980605
AU 729529	B2	20010201		
EP 998271	A1	20000510	EP 1998-931204	19980605
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000513028	T2	20001003	JP 1999-502756	19980605
US 2001018070	A1	20010830	US 1999-282233	19990329
US 6340475	B2	20020122		

PRIORITY APPLN. INFO.: US 1997-870509 A2 19970606
WO 1998-US11302 W 19980605

AB Drugs that are freely or highly sol. in water are formulated as unit dosage forms by incorporating them into polymeric matrixes comprised of high mol. wt. hydrophilic polymers that swell upon imbibition of water. The dosage form can be a single compressed **tablets**, or two or three compressed **tablets** retained in a single gelatin **capsule**. The oral formulation is designed for gastric retention and controlled delivery of an incorporated drug into the gastric cavity, and thus administered, the drug is released from the matrix into the gastric fluid by soln. diffusion. The swollen polymeric matrix, having achieved sufficient size, remains in the gastric cavity for several hours if administered while the patient is in the fed mode, and remains intact long enough for substantially all of the drug to be released before substantial erosion of the matrix occurs. The swelling matrix lowers the accessibility of the gastric fluid to the drug and thereby limits the drug release rate. This process, together with diffusion retardation by selection of specific polymers, polymer mol. wts., and other variables, results in a sustained and controlled delivery rate of the drug to the gastric environment. Controlled-release behavior of **metformin** -HCl from a polyethylene oxide matrix was demonstrated.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 99 OF 256 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2003:334870 HCAPLUS
DOCUMENT NUMBER: 138:343894
TITLE: Formulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
INVENTOR(S): Louie-helm, Jenny; Berner, Bret
PATENT ASSIGNEE(S): Depomed, Inc., USA
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003035029	A1	20030501	WO 2002-US34298	20021025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003091630 A1 20030515 US 2001-14750 20011025

PRIORITY APPLN. INFO.: US 2001-14750 A 20011025

AB Erodible, gastric-retentive dosage forms are provided that are formulated using the in vitro drug release profile obtained with USP disintegration test equipment rather the USP Dissoln. App. The invention is premised on the discovery that the USP disintegration test and modified versions thereof are far more predictive of the in vivo release profile for a controlled release dosage form than is the std. USP disintegration test, particularly controlled release dosage forms of the swellable, erodible type. The dosage forms generally comprise particles of a biocompatible, hydrophilic polymer having the active agent incorporated therein, wherein the particles are optionally but preferably compacted into a **tablet** or loaded into a **capsule**. The dosage forms can be used to deliver water-insol. or sparingly sol. drugs as well as water-sol. drugs, providing that the latter are coated with a protective **coating** or contained in a protective vesicle. **Tablet** contained BaSO4 21.35, Polyox N-60K 20.02, and Polyox N-80 58.13%.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 100 OF 256 USPATFULL on STN

ACCESSION NUMBER: 2002:185267 USPATFULL

TITLE: Dietetic food composition and dietetic method using such composition

INVENTOR(S): Zohoungbogbo, Mathias C., Torino, ITALY

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002098175	A1	20020725
APPLICATION INFO.:	US 2001-982554	A1	20011018 (9)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1999-333097, filed on 15 Jun 1999, PATENTED Continuation-in-part of Ser. No. US 1999-225819, filed on 5 Jan 1999, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1998-830365	19980616
	EP 1999-201794	19990604

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: SOFER & HAROUN, L.L.P., Suite 1921, 342 Madison Avenue, New York, NY, 10173

NUMBER OF CLAIMS: 25

EXEMPLARY CLAIM: 1

LINE COUNT: 709

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Food composition in the form of a flour comprising at least 50% of protein, less than 15% of carbohydrates and 35 to 50% of plant fibers; preferably the carbohydrate content is less than 10%, advantageously less than 5%; this composition may be used as a substitute for wheat flour in the preparation of foods such as pasta, bread, bread sticks, bakery products and pastries and constitutes the basis of a method for improving the appearance of a person by achieving a loss of weight which is beneficial from the aesthetic point of view.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

FISCAL YEAR 2004

Financial and T&A Pay Periods	PALM Pay Periods	Dates
19, 20	0401	Oct-01 - Oct-18-2003
21	0402	Oct-19 - Nov-01-2003
22	0403	Nov-02 - Nov-15-2003
23	0404	Nov-16 - Nov-29-2003
24	0405	Nov-30 - Dec-13-2003
		(End of 1st Quarter)
25	0406	Dec-14 - Dec-27-2003
26	0407	Dec-28 - Jan-10-2004
01	0408	Jan-11 - Jan-24-2004
02	0409	Jan-25 - Feb-07-2004
03	0410	Feb-08 - Feb-21-2004
04	0411	Feb-22 - Mar-06-2004
05	0412	Mar-07 - Mar-20-2004
		(End of 2nd Quarter)
06	0413	Mar-21 - Apr-03-2004
07	0414	Apr-04 - Apr-17-2004
08	0415	Apr-18 - May-01-2004
09	0416	May-02 - May-15-2004
10	0417	May-16 - May-29-2004
11	0418	May-30 - Jun-12-2004
12	0419	Jun-13 - Jun-26-2004
		(End of 3rd Quarter)
13	0420	Jun-27 - Jul-10-2004
14	0421	Jul-11 - Jul-24-2004
15	0422	Jul-25 - Aug-07-2004
16	0423	Aug-08 - Aug-21-2004
17	0424	Aug-22 - Sep-04-2004
18	0425	Sep-05 - Sep-18-2004
19	0426	Sep-19 - Sep-30-2004
		(End of 4th Quarter - EOY)

OCTOBER 2003

Sun	Mon	Tue	Wed	Thu	Fri	Sat
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31	

NOVEMBER 2003

Sun	Mon	Tue	Wed	Thu	Fri	Sat
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30						

DECEMBER 2003

Sun	Mon	Tue	Wed	Thu	Fri	Sat
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31			

JANUARY 2004

Sun	Mon	Tue	Wed	Thu	Fri	Sat
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

FEBRUARY 2004

Sun	Mon	Tue	Wed	Thu	Fri	Sat
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29						

MARCH 2004

Sun	Mon	Tue	Wed	Thu	Fri	Sat
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31			

APRIL 2004

Sun	Mon	Tue	Wed	Thu	Fri	Sat
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	

MAY 2004

Sun	Mon	Tue	Wed	Thu	Fri	Sat
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31					

JUNE 2004

Sun	Mon	Tue	Wed	Thu	Fri	Sat
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30			

JULY 2004

Sun	Mon	Tue	Wed	Thu	Fri	Sat
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

AUGUST 2004

Sun	Mon	Tue	Wed	Thu	Fri	Sat
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31				

SEPTEMBER 2004

Sun	Mon	Tue	Wed	Thu	Fri	Sat
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30		

OCTOBER 2004

Sun	Mon	Tue	Wed	Thu	Fri	Sat
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30
31						

NOVEMBER 2004

Sun	Mon	Tue	Wed	Thu	Fri	Sat
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30				

DECEMBER 2004

Sun	Mon	Tue	Wed	Thu	Fri	Sat
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31	

L Number	Hits	Search Text	DB	Time stamp
1	1	"6303146" .pn.	USPAT; US-PGPUB	2003/09/12 11:03
2	1222	metformin metomin miformidimethylbiguanide glucomine glucophage glufor gluformin diformin dimefor geamet glucamino glucofago glucoform glucomin glucomine gluconil	USPAT; US-PGPUB	2003/09/12 11:05
3	1029	glipizide glucotrol glydiazinamide glupizide glupitel glucozide glynase minidab glican glidiab digrin dipazide	USPAT; US-PGPUB	2003/09/12 11:07
4	680	(metformin metomin miformidimethylbiguanide glucomine glucophage glufor gluformin diformin dimefor geamet glucamino glucofago glucoform glucomin glucomine gluconil) and (glipizide glucotrol glydiazinamide glupizide glupitel glucozide glynase minidab glican glidiab digrin dipazide)	USPAT; US-PGPUB	2003/09/12 11:07
5	648	((metformin metomin miformidimethylbiguanide glucomine glucophage glufor gluformin diformin dimefor geamet glucamino glucofago glucoform glucomin glucomine gluconil) and (glipizide glucotrol glydiazinamide glupizide glupitel glucozide glynase minidab glican glidiab digrin dipazide)) and (coat or coating or (magnesium adj stearate) or pyrrolidone or cellulose or croscarmellose or (single adj dosage) or tablet or capsule)	USPAT; US-PGPUB	2003/09/12 11:14
6	490	(((metformin metomin miformidimethylbiguanide glucomine glucophage glufor gluformin diformin dimefor geamet glucamino glucofago glucoform glucomin glucomine gluconil) and (glipizide glucotrol glydiazinamide glupizide glupitel glucozide glynase minidab glican glidiab digrin dipazide)) and (coat or coating or (magnesium adj stearate) or pyrrolidone or cellulose or croscarmellose or (single adj dosage) or tablet or capsule)) and (magnesium adj stearate)	USPAT; US-PGPUB	2003/09/12 11:10
7	17	((((metformin metomin miformidimethylbiguanide glucomine glucophage glufor gluformin diformin dimefor geamet glucamino glucofago glucoform glucomin glucomine gluconil) and (glipizide glucotrol glydiazinamide glupizide glupitel glucozide glynase minidab glican glidiab digrin dipazide)) and (coat or coating or (magnesium adj stearate) or pyrrolidone or cellulose or croscarmellose or (single adj dosage) or tablet or capsule)) and (magnesium adj stearate)) not combination	USPAT; US-PGPUB	2003/09/12 11:10
8	23	(((metformin metomin miformidimethylbiguanide glucomine glucophage glufor gluformin diformin dimefor geamet glucamino glucofago glucoform glucomin glucomine gluconil) and (glipizide glucotrol glydiazinamide glupizide glupitel glucozide glynase minidab glican glidiab digrin dipazide)) and (coat or coating or (magnesium adj stearate) or pyrrolidone or cellulose or croscarmellose or (single adj dosage) or tablet or capsule)) not combination	USPAT; US-PGPUB	2003/09/12 11:10

9	134	((metformin metomin miformidimethylbiguanide glucomine glucophage glufor gluformin diformin dimefor geamet glucamino glucofago glucoform glucomin glucomine gluconil) and (glipizide glucotrol glydiazinamide glupizide glupitel glucozide glynase minidab glican glidiab digrin dipazide)) and ((magnesium adj stearate) and pyrrolidone or cellulose and croscarmellose)	USPAT; US-PGPUB	2003/09/12 11:14
10	75	(((metformin metomin miformidimethylbiguanide glucomine glucophage glufor gluformin diformin dimefor geamet glucamino glucofago glucoform glucomin glucomine gluconil) and (glipizide glucotrol glydiazinamide glupizide glupitel glucozide glynase minidab glican glidiab digrin dipazide)) and ((magnesium adj stearate) and pyrrolidone or cellulose and croscarmellose)) and (coating or coat)	USPAT; US-PGPUB	2003/09/12 11:15
11	17	(((metformin metomin miformidimethylbiguanide glucomine glucophage glufor gluformin diformin dimefor geamet glucamino glucofago glucoform glucomin glucomine gluconil) and (glipizide glucotrol glydiazinamide glupizide glupitel glucozide glynase minidab glican glidiab digrin dipazide)) and ((magnesium adj stearate) and pyrrolidone or cellulose and croscarmellose)) and (opadry)	USPAT; US-PGPUB	2003/09/12 11:15
12	76	(((metformin metomin miformidimethylbiguanide glucomine glucophage glufor gluformin diformin dimefor geamet glucamino glucofago glucoform glucomin glucomine gluconil) and (glipizide glucotrol glydiazinamide glupizide glupitel glucozide glynase minidab glican glidiab digrin dipazide)) and ((magnesium adj stearate) and pyrrolidone or cellulose and croscarmellose)) and (opadry or coating)	USPAT; US-PGPUB	2003/09/12 12:25
13	281	chen and metformin	USPAT; US-PGPUB; DERWENT	2003/09/12 12:26
14	233	(chen and metformin) and glipizide	USPAT; US-PGPUB; DERWENT	2003/09/12 12:26
15	4	((chen and metformin) and glipizide) and andrx	USPAT; US-PGPUB; DERWENT	2003/09/12 12:26

US 1002353308P1

Creation date: 03-04-2004
Indexing Officer: AAHMED4 - ASHA AHMED
Team: OIPEBackFileIndexing
Dossier: 10023533

Legal Date: 09-24-2003

No.	Doccode	Number of pages
1	IDS	4
2	NPL	5
3	NPL	29

Total number of pages: 38

Remarks:

Order of re-scan issued on .....